Innoveren Scientific (IVRN) 10-K 25 Mar 21 2020 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2020	Mar. 24, 2021	Jun. 30, 2020
Cover [Abstract]
Entity Registrant Name	H-CYTE, INC.
Entity Central Index Key	0001591165
Document Type	10-K
Document Period End Date	Dec. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 0
Entity Common Stock, Shares Outstanding		136,109,864
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2020

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Current Assets
Cash	$ 1,640,645	$ 1,424,096
Accounts receivable		22,667
Other receivables	22,123	18,673
Prepaid expenses	94,434	810,143
Total Current Assets	1,757,202	2,275,579
Right -of-use asset	278,552	738,453
Property and equipment, net	139,175	219,703
Other assets	29,239	36,877
Total Assets	2,204,168	3,270,612
Current Liabilities
Interest payable	6,898	53,198
Accounts payable	1,006,968	1,485,542
Accrued liabilities	276,415	324,984
Other current liabilities	154,812	175,181
Short-term notes, related party		1,635,000
Short-term convertible notes payable		424,615
Notes payable, current portion	67,444	66,836
Dividend payable		108,641
PPP Loan, current portion	606,811
Deferred revenue	634,149	1,046,156
Lease liability, current portion	139,189	453,734
Total Current Liabilities	2,892,686	5,773,887
Long-term Liabilities
Lease liability, net of current portion	157,050	302,175
Notes payable, net of current portion		11,545
Derivative liability - warrants		315,855
Redemption put liability		267,399
PPP Loan, net of current portion	202,271
Total Long-term Liabilities	359,321	896,974
Total Liabilities	3,252,007	6,670,861
Commitments and Contingencies (Note 10)
Stockholders' Equity (Deficit)
Common stock - $.001 par value: 1,600,000,000 shares authorized, 127,159,464 and 99,768,704 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively	127,159	99,769
Additional paid-in capital	42,515,999	28,172,146
Accumulated deficit	(43,858,974)	(37,362,531)
Non-controlling interest	(370,132)	(370,132)
Total Stockholders' Deficit	(1,047,839)	(9,460,742)
Total Liabilities, Mezzanine Equity and Stockholders' Deficit	2,204,168	3,270,612
Series D Convertible Preferred Stock [Member]
Mezzanine Equity
Total Mezzanine Equity		6,060,493
Series A Preferred Stock [Member]
Stockholders' Equity (Deficit)
Preferred Stock, value	538,109
Series B Convertible Preferred Stock [Member]
Stockholders' Equity (Deficit)
Preferred Stock, value		$ 6

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	1,600,000,000	1,600,000,000
Common stock, shares issued	127,159,464	99,768,704
Common stock, shares outstanding	127,159,464	99,768,704
Series D Convertible Preferred Stock [Member]
Mezzanine equity, par value	$ 0.001	$ 0.001
Mezzanine equity, shares authorized	238,871	238,871
Mezzanine equity, shares issued	0	146,998
Mezzanine equity, shares outstanding	0	146,998
Series A Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000,000	1,000,000,000
Preferred stock, shares issued	538,109,409	0
Preferred stock, shares outstanding	538,109,409	0
Series B Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000	10,000
Preferred stock, shares issued	0	6,100
Preferred stock, shares outstanding	0	6,100

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Revenues	$ 2,150,672	$ 8,346,858
Cost of Sales	(766,957)	(2,052,807)
Gross Profit	1,383,715	6,294,051
Operating Expenses
Salaries and related costs	3,198,867	8,646,471
Other general and administrative	3,746,784	6,847,335
Research and development	1,152,065	106,214
Advertising	296,873	4,909,724
Loss on impairment		15,508,401
Depreciation and amortization	81,470	834,291
Total Operating Expenses	8,476,059	36,852,436
Operating Loss	(7,092,344)	(30,558,385)
Other Income (Expense)
Other expense	(86,816)	(124,118)
Interest expense	(1,462,750)	(299,331)
Change in fair value of redemption put liability	272,704	346,696
Change in fair value of derivative liability - warrants	2,986,854	827,260
Gain on extinguishment of short-term notes, related party	1,300,088
Warrant modification expense	(70,851)
Loss on derivative instrument	(2,306,121)
Total Other Income (Expense)	633,108	750,507
Net Loss	(6,459,236)	(29,807,878)
Accrued dividends on Series B Convertible Preferred Stock	44,456	84,939
Finance costs on issuance of Series D Convertible Preferred Stock		66,265
Deemed dividend on adjustment to exercise price on convertible debt and certain warrants		287,542
Deemed dividend on Series D Convertible Preferred Stock	277,719	2,916,813
Deemed dividend on beneficial conversion features		32,592
Net Loss attributable to common stockholders	$ (6,781,411)	$ (33,196,029)
Loss per share - Basic and diluted	$ (0.06)	$ (0.34)
Weighted average outstanding shares - basic and diluted	111,491,261	96,370,562

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficit - USD ($)	Preferred Series A Stock [Member]	Preferred Series B Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Non-Controlling Interest [Member]	Total
Beginning Balance at Dec. 31, 2018			$ 33,661	$ 3,566,339	$ (9,296,408)	$ (370,132)	$ (6,066,540)
Beginning Balance, Shares at Dec. 31, 2018			33,661,388
Purchase accounting adjustments		$ 9	$ 24,717	12,657,182			12,681,908
Purchase accounting adjustments, shares		9,250	24,717,270
Adjustment for assets and liabilities not included in Merger					5,258,300		5,258,300
Issuance of Common Stock in connection with private placement offering			$ 17,700	4,402,087			4,419,787
Issuance of Common Stock in connection with private placement offering, shares			17,700,000
Issuance of warrants in connection with private placement offering				2,663,797			2,663,797
Finance costs on issuance of Series B Convertible Preferred Stock and related warrants				(132,513)			(132,513)
Issuance of common stock pursuant to conversion of short-term debt			$ 500	125,437			125,937
Issuance of common stock pursuant to conversion of short-term debt, shares			500,000
Issuance of warrants pursuant to conversion of short-term debt				74,063			74,063
Issuance of additional exchange shares			$ 17,264	(17,264)
Issuance of additional exchange shares, shares			17,263,889
Issuance of common stock pursuant to conversion of convertible short-term debt			$ 250	99,750			100,000
Issuance of common stock pursuant to conversion of convertible short-term debt, shares			250,000
Issuance of common stock pursuant to warrant exchange			$ 403	72,160			72,563
Issuance of common stock pursuant to warrant exchange, shares			403,125
Conversion of Series B Convertible Preferred Stock		$ (2)	$ 716	(714)
Conversion of Series B Convertible Preferred Stock, shares		(2,650)	715,279
Repurchase of Series B Convertible Preferred Stock		$ (1)		(49,999)			(50,000)
Repurchase of Series B Convertible Preferred Stock, shares		(500)
Issuance of common stock to pay accrued dividends on Series B Convertible Preferred Stock			$ 50	19,376			19,426
Issuance of common stock to pay accrued dividends on Series B Convertible Preferred Stock, shares			50,367
Issuance of common stock to pay accrued interest on convertible short-term debt			$ 2	665			667
Issuance of common stock to pay accrued interest on convertible short-term debt, shares			1,667
Deemed dividend on adjustment to exercise price on convertible debt and certain warrants				287,542	(287,542)
Deemed dividend on beneficial conversion features				32,592	(32,592)
Issuance of Common Stock per restricted stock award to executive			$ 4,226	1,686,028			1,690,254
Issuance of Common Stock per restricted stock award to executive, shares			4,225,634
Issuance of warrants pursuant to short-term notes, related party				56,378			56,378
Conversion of Short-term convertible notes payable - related party
Conversion of Short-term convertible notes to Preferred Stock
Issuance of warrants pursuant to conversion of Short-term convertible notes
Issuance of Common Stock in exchange for consulting fees incurred			$ 280	95,253			95,533
Issuance of Common Stock in exchange for consulting fees incurred, shares			280,085
Issuance of warrants pursuant to extension of maturity date on convertible debt				106,158			106,158
Deemed dividend on Series D Convertible Preferred Stock				(60,493)	(3,130,146)		(3,190,639)
Beneficial conversion of Series D Convertible Preferred Stock				623,045			623,045
Finance costs on issuance of Series D Convertible Preferred Stock and related warrants				(37,618)	(66,265)		(103,883)
Issuance of warrants pursuant to private placement of Series D Convertible Preferred Stock				1,893,006			1,893,006
Stock based compensation				94,828			94,828
Accrued dividends on Series B Convertible Preferred Stock				(84,939)			(84,939)
Net loss					(29,807,878)		(29,807,878)
Ending Balance at Dec. 31, 2019		$ 6	$ 99,769	28,172,146	(37,362,531)	(370,132)	(9,460,742)
Ending Balance, shares at Dec. 31, 2019		6,100	99,768,704
Adjustment of exercise price on certain warrants				(438,913)			(438,913)
Reclassification of Series B warrants to equity				73,805			73,805
Reclassification of Series D warrants to equity				337,400			337,400
Conversion of Series B Convertible Preferred Stock to Common Stock		$ (6)	$ 2,120	150,983			153,097
Conversion of Series B Convertible Preferred Stock to Common Stock, shares		(6,100)	2,119,713
Conversion of Series D Convertible Preferred Stock to Common Stock			$ 15,773	6,422,441			6,438,214
Conversion of Series D Convertible Preferred Stock to Common Stock, shares			15,773,363
Conversion of Short-term convertible notes payable - related party	$ 35,860			412,541			448,401
Conversion of Short-term convertible notes payable - related party, shares	35,860,079
Conversion of April Advance notes - related party	$ 198,194			2,579,961			2,778,155
Conversion of April Advance notes - related party, shares	198,194,248
Conversion of Short-term convertible notes to Preferred Stock	$ 89,790			1,167,271			1,257,061
Conversion of Short-term convertible notes to Preferred Stock, shares	89,790,089
Issuance of warrants pursuant to conversion of Short-term convertible notes				1,004,252			1,004,252
Issuance of Common Stock in connection with extinguishment of short-term notes, related party			$ 4,368	214,046			218,414
Issuance of Common Stock in connection with extinguishment of short term notes, related parties, shares			4,368,278
Deemed dividend on Series D Convertible Preferred Stock				(277,719)			(277,719)
Deemed dividend on Series D Convertible Preferred Stock at issuance					(37,207)		(37,207)
Reclassification of related party warrants to equity				107,123			107,123
Issuance of Common Stock in exchange for consulting fees incurred			$ 109	34,891			35,000
Issuance of Common Stock in exchange for consulting fees incurred, shares			109,375
Issuance of warrants pursuant to private placement of Series D Convertible Preferred Stock				31,902			31,902
Issuance of warrants pursuant to extension of convertible short-term notes, related party				17,636			17,636
Issuance of warrants pursuant to extension of maturity date on convertible debt				6,595			6,595
Stock based compensation				643			643
Accrued dividends on Series B Convertible Preferred Stock				(44,456)			(44,456)
Issuance of Series A Preferred Stock in Rights Offering, net of issuance costs	$ 218,285			2,517,451			2,735,736
Issuance of Series A Preferred Stock in Rights Offering, net of issuance costs, shares	218,285,024
Conversion of Series A Preferred Stock to Common Stock	$ (4,020)		$ 4,020
Conversion of Series A Preferred Stock to Common Stock, shares	(4,020,031)		4,020,031
Conversion of warrants to Common Stock			$ 1,000	26,000			27,000
Conversion of warrants to Common Stock, shares			1,000,000
Net loss					(6,459,236)		(6,459,236)
Ending Balance at Dec. 31, 2020	$ 538,109		$ 127,159	$ 42,515,999	$ (43,858,974)	$ (370,132)	$ (1,047,839)
Ending Balance, shares at Dec. 31, 2020	538,109,409		127,159,464

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash Flows from Operating Activities
Net loss	$ (6,459,236)	$ (29,807,878)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	81,470	834,291
Loss on impairment		15,508,401
Loss on asset disposal	1,342
Amortization of debt discount	1,395,007	152,342
Interest and penalties on extension of short-term convertible notes		85,365
Stock-based compensation	643	1,785,082
Loss on write-off of inventory		131,455
Common stock issued for consulting services	35,000	95,533
Income from change in fair value adjustment of derivative liability - warrants	(2,986,854)	(827,260)
Change in fair value of redemption put liability	(272,704)	(346,696)
Change in fair value of Derivative Liability - Day one derivative loss	2,306,121
Issuance of warrants to extend short-term debt, related party	17,636
Bad debt expense	6,000	90,137
Issuance of warrants pursuant to extension of maturity date on convertible debt	6,595	106,158
Issuance of Common Stock pursuant to warrant exchange	27,000
Gain on extinguishment of short-term notes, related party	(1,300,088)
Warrant modification expense	70,851
Changes in operating assets and liabilities, net of purchase transaction :
Accounts receivable	16,667	48,195
Other receivables	(3,450)	(13,529)
Prepaid expenses and other assets	723,578	(697,529)
Interest payable	36,196	(10,592)
Accounts payable	(478,572)	121,907
Accrued liabilities	(48,569)	(263,874)
Other current liabilities	(20,369)	(2,875)
Deferred revenue	(412,007)	720,092
Net Cash Used in Operating Activities	(7,257,743)	(12,291,275)
Cash Flows from Investing Activities
Purchase of property and equipment	(2,284)	(20,686)
Purchase of business, net of cash acquired		(302,710)
Net assets not included in purchase transaction		(69,629)
Net Cash Used in Investing Activities	(2,284)	(393,025)
Cash Flows from Financing Activities
Proceeds from short-term related party notes		1,635,000
Payment of dividends		(14,684)
Proceeds from Paycheck Protection Plan	809,082
Payment on debt obligations	(10,937)	(370,636)
Proceeds from common stock, net of issuance costs		4,337,106
Proceeds from Secured Convertible Promissory Notes	3,842,695	2,613,965
Proceeds from issuance of Series D Convertible Preferred Stock, net of issuance costs	100,000	5,888,017
Proceeds from Preferred stock Series A, net of issuance costs	2,735,736
Payment on Preferred stock Series B Convertible Preferred Stock redemption		(50,000)
Net Cash Provided by Financing Activities	7,476,576	14,038,768
Net Increase in Cash	216,549	1,354,468
Cash - Beginning of period	1,424,096	69,628
Cash - End of period	1,640,645	1,424,096
Supplementary Cash Flow Information
Cash paid for interest	33,136	197,500
Non-cash investing and financing activities
Common stock issued to pay accrued dividends		19,426
Deemed dividend on adjustment to exercise price on convertible debt and certain warrants		287,542
Deemed dividend on beneficial conversion feature		32,592
Deemed dividend on Series D Convertibl Preferred Stock	314,926	3,190,639
Conversion of debt obligations to Common Stock		225,937
Conversion of Series D Convertible Preferred Stock and accrued dividends to Common Stock	6,438,214	623,045
Reclassification of related party warrants to equity	107,123
Reclassification of Series B warrants to equity	73,805
Reclassification of Series D warrants to equity	337,400
Conversion of debt obligations to warrants		74,063
Issuance of warrants pursuant to note payable, related party		56,378
Conversion of Series B Convertible Preferred Stock and accrued dividends to Common Stock	153,097
Conversion of Short-term convertible notes payable, related party	448,401
Conversion of April Advance notes-related parties	2,778,155
Conversion of Short-term convertible notes to Preferred Stock	1,257,061
Issuance of warrants pursuant to conversion of short-term convertible notes	1,004,252
Dividends accrued on Series B Convertible Preferred Stock	44,456	65,512
Adjustment of exercise price on certain warrants	438,913
Issuance of Common Stock in connection with extinguishment of short term notes, related party	218,414
Issuance of warrants pursuant to private placement of Series D Convertible Preferred Stock	31,902	1,893,006
Right-of-use asset additions		1,165,785
Right-of-use liability		$ 1,187,991

Description of the Company

Description of the Company	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Description of the Company	Note 1 – description of the company H-CYTE, Inc is a hybrid-biopharmaceutical company dedicated to developing and delivering new treatments for patients with chronic respiratory and pulmonary disorders. During the last 18 months, the Company has evolved into two separate verticals under its Healthcare Medical Biosciences Division with its entrance into the biologics development space (“Biologics Vertical”). This new vertical is complementary to the Company’s current Lung Health Institute (LHI) autologous infusion therapy business (“Infusion Vertical”) and is focused on underserved disease states. On July 11, 2019, MedoveX Corp. (“MedoveX”) changed its name to H-CYTE, Inc. (“H-CYTE” or the “Company”) by filing a Certificate of Amendment (the “Amendment”) to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) with the Secretary of the State of Nevada. The name change and the Company’s new symbol, HCYT, became effective with FINRA on July 15, 2019. H-CYTE was incorporated in Nevada on July 30, 2013 as SpineZ Corp. On October 18, 2018, H-CYTE (formerly named MedoveX) entered into an Asset Purchase Agreement (“APA”) with Regenerative Medicine Solutions, LLC, RMS Shareholder, LLC (“Shareholder”), Lung Institute LLC (“LI”), RMS Lung Institute Management LLC (“RMS LI Management”) and Cognitive Health Institute Tampa, LLC (“CHIT”), (collectively “RMS”). On January 8, 2019, the APA was amended, and the Company acquired certain assets and assumed certain liabilities of RMS as reported in the 8-K/A filed in March of 2019. Based on the terms of the APA and its amendment (collectively the “APA”), the former RMS members had voting control of the combined company as of the closing of the RMS acquisition. For accounting purposes, the acquisition transaction has been treated as a reverse acquisition whereby the Company is deemed to have been acquired by RMS and the historical financial statements prior to the acquisition date of January 8, 2019 now reflect the historical financial statements of RMS. As of the merger, the consolidated results for H-CYTE include the following wholly-owned subsidiaries: H-CYTE Management, LLC (formerly Blue Zone Health Management, LLC), MedoveX Corp, Cognitive Health Institute, LLC, and Lung Institute Tampa, LLC (formerly Blue Zone Lung Tampa, LLC) and the results included Lung Institute Dallas, PLLC (“LI Dallas”), Lung Institute Nashville, PLLC (“LI Nashville”), Lung Institute Pittsburgh, PLLC (“LI Pittsburgh”), and Lung Institute Scottsdale, LLC (“LI Scottsdale”), as Variable Interest Entities (“VIEs”). H-CYTE Management, LLC is the operator and manager of the various Lung Health Institute (LHI) clinics: LI Dallas, LI Nashville, LI Pittsburgh, and LI Scottsdale. On September 11, 2020, with the closing of the Rights Offering, FWHC, LLC, FWHC, Bridge, LLC, and FWHC Bridge Friends, LLC (collectively known as “FWHC”) gained control of the Company by subsequently owning approximately 61% of the fully diluted shares of the Company (see Notes 8 and 9). Company’s Two Operating Divisions The Company has two divisions: the Healthcare Medical Biosciences Division (“which includes the Infusion Vertical and the Biologics Vertical”) and the DenerveX medical device division (“DenerveX”). The Company has decided to focus its available resources on the Medical Biosciences Division as it represents a significantly greater opportunity than the DenerveX division. The Company is no longer manufacturing or selling the DenerveX device but continues to explore possible opportunities to monetize such technology. Healthcare Medical Biosciences Division (Biosciences Division) Autologous Infusion Therapy (“Infusion Vertical”) The Company’s Biosciences includes the Infusion Business that develops and implements innovative treatment options in autologous cellular therapy (PRP-PBMC) to treat chronic lung disorders. Committed to an individualized patient-centric approach, this division consistently provides oversight and management of the highest quality care to the LHI clinics located in Tampa, Nashville, and Scottsdale, while producing positive medical outcomes following the strictest CDC guidelines. Biotech Development Division (“Biologics Vertical”) On June 21, 2019, H-CYTE entered into an exclusive product supply agreement with Rion, LLC (“Rion”) to develop and distribute (post FDA approval) a biologic for chronic obstructive pulmonary disease (“COPD”), the fourth leading cause of death in the U.S. Rion has established a novel biologics technology to harness the healing power of the body. Rion’s innovative technology, based on science developed at Mayo Clinic, provides an off-the-shelf platform to enhance healing in soft tissue, musculoskeletal, cardiovascular and neurological organ systems. This agreement provides for a 10-year exclusive and extendable supply agreement with Rion to enable H-CYTE to develop proprietary biologics. On October 9, 2019, the Company entered into a services agreement with Rion which provides the Company the benefit of Rion’s resources and expertise for the limited purpose of (i) consulting with and assisting H-CYTE in the further research and development for the generation of a new biologic and (ii) subsequently assisting H-CYTE in seeking and obtaining FDA Phase 1 IND clearance for this biologic as necessary. Rion also agrees to consult with H-CYTE in its arrangement for services from third parties unaffiliated with Rion to support research, development, regulatory approval, and commercialization of the biologic. With these agreements, Rion will serve as the product supplier and contracted preclinical development arm of the biologic. H-CYTE will control the commercial development and the clinical trial investigation. After conducting the clinical efficacy trials of this biologic, H-CYTE intends to pursue submission of a Biologics License Application (“BLA”) for review by the FDA for treatment of COPD. Proprietary Medical Device Business (DenerveX division) In the first quarter of 2020, the Company made the decision to stop any further efforts to source alternative manufacturing and distributor options or other product relationships for the DenerveX product. Although the Company believes the DenerveX technology has value, the Company did not believe it would realize value in the foreseeable future. The Company recorded an impairment charge for intangibles associated with the DenerveX intellectual property and wrote off related inventory balances as of December 31, 2019. The Company is no longer manufacturing or selling the DenerveX device but continues to explore possible opportunities to monetize such technology.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	Note 2 – Basis Of Presentation And Summary of Significant Accounting Policies Based on the terms of the APA, the former RMS members had voting control of the combined company as of the closing of the Merger. RMS is deemed to be the acquiring company for accounting purposes and the transaction is accounted for as a reverse acquisition under the acquisition method of accounting for business combinations in accordance with U.S. GAAP. The assets acquired and the liabilities assumed of RMS included as part of the purchase transaction are recorded at historical cost. Accordingly, the assets and liabilities of H-CYTE are recorded as of the Merger closing date at their estimated fair values. The consolidated balance sheets, consolidated statements of operations, consolidated statements of stockholders’ deficit, and the consolidated statements of cash flows do not reflect the historical financial information related to H-CYTE prior to the Merger as they only reflect the historical financial information related to RMS. For the consolidated statements of stockholders’ deficit, the common stock, preferred stock, and additional paid in capital reflect the accounting for the stock received by the RMS members as of the Merger as if it was received at the beginning of the periods presented. Principles of Consolidation U.S. GAAP requires that a related entity be consolidated with a company when certain conditions exist. An entity is considered to be a VIE when it has equity investors who lack the characteristics of having a controlling financial interest, or its capital is insufficient to permit it to finance its activities without additional subordinated financial support. Consolidation of a VIE by the Parent would be required if it is determined that the Parent will absorb a majority of the VIE’s expected losses or residual returns if they occur, retain the power to direct or control the VIE’s activities, or both. The accompanying audited consolidated financial statements include the accounts of the Parent, its wholly owned subsidiaries, and its VIEs. All intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates In preparing the financial statements, U.S. GAAP requires disclosure regarding estimates and assumptions used by management that affect the amounts reported in financial statements and accompanying notes. Significant estimates were made around the valuation of embedded derivatives, which impacts gains or losses on such derivatives, the carrying value of debt, interest expense, and deemed dividends. Actual results could differ from those estimates. Cash The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The Company’s cash balances at December 31, 2020 and 2019 consists of funds deposited in checking accounts with commercial banks. Accounts Receivable Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables. Trade accounts receivable are stated net of an estimate made for doubtful accounts, if any. Management evaluates the adequacy of the allowance for doubtful accounts regularly to determine if any account balances will potentially be uncollectible. Customer account balances are considered past due or delinquent based on the contractual agreement with each customer. Accounts are written off when, in management’s judgment, they are considered uncollectible. At December 31, 2020 and 2019, management believes no allowance is necessary. For the year ended December 31, 2020 and 2019, the Company recorded bad debt expense of approximately $6,000 and $90,000, respectively. Impairment of Long-Lived Assets The Company reviews the values assigned to long-lived assets, including property and equipment and certain intangible assets, to determine whether events and circumstances have occurred which indicate that the remaining estimated useful lives may warrant revision or that the remaining balances may not be recoverable. The evaluation of asset impairment requires management to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment, and actual results may differ from estimated amounts. In such reviews, undiscounted cash flows associated with these assets are compared with their carrying value to determine if a write-down to fair value is required (see Note 7). Goodwill Goodwill represents the excess of purchase price over fair value of net identified tangible and intangible assets and liabilities acquired. The Company does not amortize goodwill; it tests goodwill for impairment on at least an annual basis. An impairment loss, if any, is measured as the excess of the carrying value of the reporting unit over the fair value of the reporting unit (see Note 7). Leases In February 2016, the Financial Accounting Standard Board (“FASB”) established Topic 842, Leases, by issuing Accounting Standards Update (ASU) No. 2016-02 (as amended), which requires lessees to recognize leases on the balance sheet and disclose key information about leasing arrangements. The new standard establishes a right-of-use (“ROU”) model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than twelve months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. The Company has not entered into significant lease agreements in which it is the lessor. For the lease agreements in which the Company is the lessee, under Topic 842, lessees are required to recognize a lease liability and right-of-use asset for all leases (except for short-term leases) at the lease commencement date. Effective January 1, 2019, the Company adopted this guidance, applied the modified retrospective transition method and elected the transition option to use the effective date as the date of initial application. The Company recognized the cumulative effect of the transition adjustment on the consolidated balance sheet as of the effective date and did not provide any new lease disclosures for periods before the effective date. With respect to the practical expedients, the Company elected the package of transitional-related practical expedients and the practical expedient not to separate lease and non-lease components. Other Receivables Other receivables totaling approximately $22,000 and $19,000 at December 31, 2020 and 2019, respectively include receivables from the non-acquired Lung Institute, LLC due to Lung Institute Tampa, LLC for approximately $3,000 and $10,000. Other receivables totaling approximately $19,000 and $9,000 include reimbursement receivables for expenses from RMS at December 31, 2020 and 2019, respectively. Revenue Recognition The Company recognizes revenue in accordance with U.S. GAAP as outlined in the FASB ASC 606, Revenue From Contracts with Customers The Company uses a standard pricing model for the types of cellular therapy treatments that is offered to its patients. The transaction price accounts for medical, surgical, facility, and office services rendered by the Company for consented procedures and is recorded as revenue. The Company recognizes revenue when the terms of a contract with a patient are satisfied. The Company offers two types of cellular therapy treatments to their patients. 1) The first type of treatment includes medical services rendered typically over a two-day period in which the patient receives cellular therapy. For this treatment type, revenue is recognized in full at time of service. 2) The Company also offers a four-day treatment in which medical services are rendered typically over a two-day period and then again, approximately three months later, medical services are rendered for an additional two days of treatment. Payment is collected in full for both service periods at the time the first treatment is rendered. Revenue is recognized when services are performed based on the estimated standalone selling price of each service. The Company has deferred recognition of revenue amounting to approximately $634,000 and $1,046,000 at December 31, 2020 and 2019, respectively. The Company’s policy is to not offer refunds to patients. However, in limited instances the Company may make exceptions to this policy for extenuating circumstances. These instances are evaluated on a case-by-case basis and may result in a patient refund. Management performed an analysis of its customer refund history for refunds issued related to prior year’s revenue. Management used the results of this historical refund analysis to record a reserve for anticipated future refunds related to recognized revenue. At December 31, 2020 and 2019, the estimated allowance for refunds was approximately $77,000 and $63,000, respectively and is recorded in a contra revenue account. Research and development costs Research and development expenses are recorded in operating expenses in the period in which they are incurred. Advertising Advertising costs are recorded in operating expenses in the period in which they are incurred. Stock-Based Compensation The Company maintains a stock option incentive plan and accounts for stock-based compensation in accordance with ASC 718, Compensation - Stock Compensation Income Taxes The Company utilizes the liability method of accounting for income taxes as set forth in FASB ASC Topic 740, “Income Taxes”. Under the liability method, deferred taxes are determined based on temporary differences between the financial statement and tax bases of assets and liabilities using tax rates expected to be in effect during the years in which the difference turns around. The Company accounts for interest and penalties on income taxes as income tax expense. A valuation allowance is recorded when it is more likely than not that a tax benefit will not be realized. In determining the need for valuation allowances the Company considers projected future taxable income and the availability of tax planning strategies. From inception to December 31, 2020, the Company has incurred net losses and, therefore, has no current income tax liability. The net deferred tax asset generated by these losses is fully offset by a valuation allowance as of December 31, 2020 and 2019 since it is currently likely that the benefit will not be realized in future periods. There are no uncertain tax positions at December 31, 2020 and 2019. The Company has not undergone any tax examinations since inception. Net Loss Per Share Basic loss per share is computed on the basis of the weighted average number of shares outstanding for the reporting period. Diluted loss per share is computed on the basis of the weighted average number of common shares plus potentially dilutive common shares outstanding using the treasury stock method. Any potentially dilutive securities are antidilutive due to the Company’s net losses. Fair Value Measurements The Company measures certain non-financial assets, liabilities, and equity issuances at fair value on a non-recurring basis. These non-recurring valuations include evaluating assets such as long-lived assets and non-amortizing intangible assets for impairment; allocating value to assets in an acquired asset group; and applying accounting for business combinations. The Company classifies its stock warrants as either liability or equity instruments in accordance with ASC 480, “Distinguishing Liabilities from Equity” (ASC 480) and ASC 815, “Derivatives and Hedging” (ASC 815), depending on the specific terms of the warrant agreement. The Company uses the fair value measurement framework to value these assets and report the fair values in the periods in which they are recorded, adjusted above, or written down. The fair value measurement framework includes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair values in their broad levels. These levels from highest to lowest priority are as follows: ● Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities; ● Level 2: Quoted prices in active markets for similar assets or liabilities or observable prices that are based on inputs not quoted on active markets, but corroborated by market data; and ● Level 3: Unobservable inputs or valuation techniques that are used when little or no market data is available. The determination of fair value and the assessment of a measurement’s placement within the hierarchy requires judgment. Level 3 valuations often involve a higher degree of judgment and complexity. Level 3 valuations may require the use of various cost, market, or income valuation methodologies applied to unobservable management estimates and assumptions. Management’s assumptions could vary depending on the asset or liability valued and the valuation method used. Such assumptions could include estimates of prices, earnings, costs, actions of market participants, market factors, or the weighting of various valuation methods. The Company may also engage external advisors to assist us in determining fair value, as appropriate. The Company evaluates its financial liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments to be made. Although the Company believes that the recorded fair value of our financial instruments is appropriate at December 31, 2020, these fair values may not be indicative of net realizable value or reflective of future fair values.

Liquidity, Going Concern and Ma

Liquidity, Going Concern and Management's Plans	12 Months Ended
	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity, Going Concern and Management's Plans	Note 3 - Liquidity, Going Concern and Management’s Plans The Company incurred net losses of approximately $6,459,000 for the year ending December 31, 2020. The Company used approximately $7,258,000 in net cash from operating activities for the year ending December 31, 2020 and has historically incurred losses from operations and expects to continue to generate negative cash flows as the Company implements its business plan. The consolidated financial statements are prepared using generally accepted accounting principles in the United States (“U.S. GAAP”) as applicable to a going concern. COVID-19 has adversely affected the Company’s financial condition and results of operations. The impact of the outbreak of COVID-19 on the economy in the U.S. and the rest of the world is expected to continue to be significant. The extent to which the COVID-19 outbreak will continue to impact the economy is highly uncertain and cannot be predicted. Accordingly, the Company cannot predict the extent to which its financial condition and results of operations will be affected. The Company has updated its business model to decrease corporate overhead and marketing expense to significantly reduce expenses. The Company believes that as COVID-19 begins to dissipate due to vaccinations being administered nationwide, patients will again feel comfortable traveling to one of the LHI clinics for treatment. The Company’s Biologics Vertical has commenced preclinical work in support of filing an Investigational New Drug Application (“IND”) with the U.S. Food and Drug Administration (“FDA”). The Company is anticipating an initial submission during the second half of 2021. The Company had cash on hand of approximately $1,641,000 as of December 31, 2020 and approximately $436,000, as of March 24, 2021. The Company’s cash is insufficient to fund its operations over the next year and the Company is currently working to obtain additional debt or equity financing to help support short-term working capital needs. There can be no assurance that the Company will be able to raise additional funds or that the terms and conditions of any future financings will be workable or acceptable to the Company or its shareholders. If the Company is unable to fund its operations from existing cash on hand, operating cash flows, additional borrowings, or raising equity capital, the Company may be forced to discontinue operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Business Acquisition

Business Acquisition	12 Months Ended
	Dec. 31, 2020
Business Combinations [Abstract]
Business Acquisition	Note 4– Business Acquisition On January 8, 2019, MedoveX completed its business combination with RMS under which MedoveX purchased certain assets and assumed certain liabilities of RMS, otherwise referred to as the Merger. Pursuant to the terms of the APA, MedoveX issued to the shareholders of RMS 33,661 shares plus 6,111 additional Exchange Shares (based on closing the sale of $2 million of new securities) for a total of 39,772 shares of Series C Preferred Stock where each share of Series C Preferred stock automatically converted into 1,000 shares of common stock and represent approximately 55% of the outstanding voting shares of the Company. Under the terms of the APA, the Company issued additional “Exchange Shares” to the shareholders of RMS to maintain the 55% ownership and not be diluted by the sale of convertible securities (“New Shares Sold”) until MedoveX raised an additional $5.65 million via the issuance of new securities. On the date of closing the Company issued 6,111 additional Exchange Shares to RMS Shareholders as a result of the issuance of additional securities, which are included in the 39,772 shares above. Subsequent to the closing of the purchase transaction, an incremental 11,153 additional Exchange Shares were issued, for a total of 17,264 additional Exchange Shares. All additional Exchange Shares have been issued to the shareholders of RMS and these Series C Preferred shares converted to 17,263,889 shares of common stock; no additional equity will be issued to RMS. Because RMS shareholders owned approximately 55% of the voting stock of MedoveX after the transaction, RMS was deemed to be the acquiring company for accounting purposes (the “Acquirer”) and the transaction is accounted for as a reverse acquisition under the acquisition method of accounting for business combinations in accordance with U.S. GAAP. The assets acquired and the liabilities assumed of RMS included as part of the purchase transaction are recorded at historical cost. Accordingly, the assets and liabilities of MedoveX (the “Acquiree”) are recorded as of the Merger closing date at their estimated fair values. Under the terms of the APA, MedoveX purchased certain assets and assumed certain liabilities of RMS. The assets of RMS reported on the MedoveX consolidated balance sheet as of December 31, 2018 that were excluded in the Merger on January 8, 2019 included the following: cash of approximately $70,000 convertible debt to a related party of approximately $4,300,000, interest payable of approximately $158,000, short-term notes, related party of approximately $180,000, accounts payable of approximately $398,000 and other current liabilities of approximately $285,000. Additionally, there were certain on-going litigation matters that were not assumed as part of the January 8, 2019 Merger. Purchase Price Allocation The purchase price for the acquisition of the Acquiree has been allocated to the assets acquired and liabilities assumed based on their estimated fair values. The acquisition-date fair value of the consideration transferred is as follows: Common shares issued and outstanding 24,717,270 Common shares reserved for issuance upon conversion of the outstanding Series B Preferred Stock 2,312,500 Total Common shares 27,029,770 Closing price per share of MedoveX Common stock on January 8, 2019 $ 0.40 10,811,908 Fair value of outstanding warrants and options 2,220,000 Cash consideration to RMS (350,000 ) Total consideration $ 12,681,908 Prior to the transaction, MedoveX had 24.5 million shares of common stock outstanding at a market capitalization of $9.8 million. The estimated fair value of the net assets of MedoveX was $8.4 million as of January 8, 2019. Measuring the fair value of the net assets to be received by RMS was readily determinable based upon the underlying nature of the net assets. The fair value of the MedoveX common stock is above the fair value of its net assets. The MedoveX net asset value is primarily comprised of definite-lived intangibles as of the closing and the RMS interest in the merger is significantly related to obtaining access to the public market. Therefore, the fair value of the MedoveX stock price and market capitalization as of the closing date is considered to be the best indicator of the fair value and, therefore, the estimated purchase price consideration. The following table summarizes the fair values of the assets acquired and liabilities assumed at the date of acquisition on January 8, 2019: Cash $ (302,710 ) Accounts receivable 145,757 Inventory 131,455 Prepaid expenses 46,153 Property and equipment 30,393 Other 2,751 Intangibles 3,680,000 Goodwill 12,564,401 Total assets acquired $ 16,298,200 Accounts payable and other accrued liabilities 1,645,399 Derivative liability 1,215,677 Interest-bearing liabilities and other 755,216 Net assets acquired $ 12,681,908 Intangible assets are recorded as definite-lived assets and amortized over the estimated period of economic benefit. Intangible assets represent the fair value of patents and related proprietary technology for the DenerveX System. During the fourth quarter of 2019 the Company recorded an impairment charge of $2,944,000 related to the carrying value of its intangible assets (see Note 7). Goodwill is calculated as the difference between the acquisition-date fair value of the consideration transferred and the fair values of the assets acquired and liabilities assumed. Goodwill is not expected to be deductible for income tax purposes. Goodwill is recorded as an indefinite-lived asset and is not amortized but tested for impairment on an annual basis or when indications of impairment exist. During the fourth quarter of 2019 the Company recorded an impairment charge of approximately $12,564,000 related to the carrying value of goodwill (see Note 7). The derivative liability relates to the liability associated with warrants issued with the securities purchase agreements executed in May 2018, which liability was assumed in the Merger (see Note 12). Total interest-bearing liabilities and other liabilities assumed are as follows: Notes payable $ 99,017 Short-term convertible notes payable 598,119 Dividend payable 57,813 Deferred rent 267 Total interest-bearing and other liabilities $ 755,216 Notes payable relate to promissory notes assumed by Acquiree in a 2015 acquisition, which was later divested in 2016, with the assumed promissory notes being retained by Acquiree. The Company finalized an eighteen-month extension on the notes extending the maturity date to March 1, 2021. Payments on both notes are due in aggregate monthly installments of approximately $5,800 and carry an interest rate of 5%. The promissory notes had outstanding balances of approximately $99,000 plus accrued interest of approximately $3,000 at January 8, 2019 (see Note 11) and promissory notes had outstanding balances of approximately $67,000 and $78,000 at December 31, 2020 and 2019. The Company has not made payments on this note since February 10, 2020, due to COVID-19, resulting in accrued interest of approximately $1,900. In the third quarter of 2018, convertible notes were issued pursuant to a securities purchase agreement with select accredited investors, whereby the Acquiree offered up to 1,000,000 units (the “Units”) at a purchase price of $50,000 per Unit. Each Unit consisted of (i) a 12% senior secured convertible note, initially convertible into shares of the Company’s common stock, par value $0.001 per share, at a conversion price equal to the lesser of $0.40 or ninety percent (90%) of the per share purchase price of any shares of common stock or common stock equivalents issued in future private placements of equity and/or debt securities completed by the Company following this offering of Units, and (ii) a three-year warrant to purchase such number of shares of the Company’s common stock equal to one hundred percent (100%) of the number of shares of common stock issuable upon conversion of the notes at $0.40. The warrants are exercisable at a price equal to the lesser of $0.75 or ninety percent (90%) of the per share purchase price of any shares of common stock or common stock equivalents issued in future private placements of the debt and/or equity securities completed by the Company following the issuance of warrants. As a result of the price adjustment feature, the conversion price of the convertible notes was adjusted to $0.36 per share. In the offering, the Acquiree sold an aggregate of 15 Units and issued to investors an aggregate of $750,000 in principal amount of convertible notes and 1,875,000 warrants to purchase common stock, resulting in total gross proceeds of $750,000 to the Company. If converted at $0.40 the convertible notes sold in the offering are convertible into an aggregate of 1,875,000 shares of common stock. The Acquiree recorded the proceeds from the notes and the accompanying warrants, which accrete over the period the notes are outstanding, on a relative fair value basis of approximately $505,000 and $245,000, respectively. At acquisition date, the value of the notes was approximately $598,000. Due to the notes maturing in 2019, the warrants have fully accreted as of December 31, 2019. The convertible notes had maturity dates between August and September 2019 and were renegotiated or repaid during the third and fourth quarters of 2019 (see Note 11). The following schedule represents the amount of revenue and net loss attributable to the MedoveX acquisition which have been included in the consolidated statements of operations for the periods subsequent to the acquisition date: For the Year Ended December 31, 2019 Revenues $ 67,631 Net loss attributable to MedoveX $ (4,754,680 )

Right-of-use Asset and Lease Li

Right-of-use Asset and Lease Liability	12 Months Ended
	Dec. 31, 2020
Leases [Abstract]
Right-of-use Asset and Lease Liability	Note 5 – Right-of-use Asset And Lease Liability Upon adoption of ASU No. 2016-02 (as amended), additional current liabilities of approximately $475,000 and long-term liabilities of approximately $713,000 with corresponding ROU assets of approximately $1,167,000 were recognized, based on the present value of the remaining minimum rental payments under the new leasing standard for existing operating leases. The consolidated balance sheet at December 31, 2020 reflects current lease liabilities of approximately $139,000 and long-term liabilities of $157,000, with corresponding ROU assets of $279,000. The components of lease expense, included in other general and administrative expense, for the years ended December 31, 2020 and 2019, respectively, are as follows: December 31, 2020 December 31, 2019 Operating lease expense $ 548,622 $ 579,770 Cash paid for amounts included in the measurement of lease liabilities for the years ended December 31, 2020 and 2019, respectively, are as follows: December 31, 2020 December 31, 2019 Operating cash flows from operating leases $ 548,622 $ 579,770 Supplemental balance sheet and other information related to operating leases are as follows: December 31, 2020 December 31, 2019 Operating leases: Operating leases right-of-use assets $ 278,552 $ 738,453 Lease liability, current 139,189 453,734 Lease liability, net of current portion 157,050 302,175 Total operating lease liabilities $ 296,239 755,909 Weighted average remaining lease term 2.32 years 2.2 years Weighted average discount rate 10.31 % 7.75 % Maturities of operating lease liabilities as of December 31, 2020 are as follows: December 31, 2020 Due in one year or less $ 154,559 Due after one year through two years 102,891 Due after two years through three years 69,333 Total lease payments 326,783 Less interest (30,544 ) Total $ 296,239 Operating lease expense and cash flows from operating leases and short-term leases for years ended December 31, 2020 and 2019 totaled approximately $570,000 and $580,000, respectively, and are included in the “Other general and administrative” section of the consolidated statement of operations. Additionally, the Company entered into a short-term lease for its Nashville location beginning November 1, 2020 totaling $73,750 a with maturity date of October 31, 2021, and will be entering into a short-term lease for its Tampa location beginning April 1, 2021 totaling $71,775 with a maturity date of March 31, 2022. The Company leases corporate office space in Tampa, FL and Atlanta, GA. The Company also leases medical clinic space in Tampa, FL, Nashville, TN, Scottsdale, AZ, Pittsburgh, PA, and Dallas, TX. The leasing arrangements contain various renewal options that are adjusted for increases in the consumer price index or agreed upon rates. Each location has its own expiration date ranging from April 30, 2020 to August 31, 2023. The Company did not renew the leases in Dallas, TX, Pittsburgh, PA, and Atlanta, GA as those leases all expired in 2020. The Company does not intend on renewing its corporate office space lease in Tampa, FL which expires on March 31, 2021 but will renew the Tampa, FL lease for the LHI clinic. The Company has decided that its corporate staff will continue working remotely but the Company will have a small corporate meeting room in the Tampa LHI clinic.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 6 - Property and Equipment Property and equipment, net, consists of the following: Useful Life December 31, 2020 December 31, 2019 Furniture and fixtures 5-7 years $ 231,222 $ 231,222 Computers and software 3-7 years 246,323 244,039 Leasehold improvements 15 years 155,583 157,107 633,128 632,368 Less accumulated depreciation (493,953 ) (412,665 ) Total $ 139,175 $ 219,703 Depreciation expense was approximately $81,000 and $98,000, respectively, for the years ended December 31, 2020 and 2019. The Company uses the straight-line depreciation method to calculate depreciation expense.

Intangible Assets and Goodwill

Intangible Assets and Goodwill	12 Months Ended
	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	Note 7 - Intangible Assets and Goodwill The Company’s intangible assets are patents and related proprietary technology for the DenerveX System. For the year ended December 31, 2019, total amortization expense related to acquisition-related intangible assets was $736,000 and included in operating expense in the accompanying consolidated statement of operations. The Company decided to suspend the manufacturing and sale of the DenerveX product as it has been unsuccessful in its attempts to source cost effective alternative manufacturing and distributor options for the product. The Company has no future plans to commit any additional resources related to the future development or sales efforts for the product, as it has determined that the cost to relaunch the product back to market to be significant and indeterminable due to issues with the manufacturing and sterilization of the product. The DenerveX System no longer represents part of the Company’s core strategic plans for the future. The Company believes that it is more likely than not, that the carrying value will not be recoverable. As a result, during the fourth quarter of 2019 the Company recorded a charge of $2,944,000 to impair the carrying value of the technology related intangible. This charge was recorded within the caption, “Loss on impairment” in the accompanying consolidated statements of operations. The Company’s goodwill balance was determined to be impaired as of the balance sheet date due to the adverse financial results for 2019, the negative projected cash results for 2020 and a significant decline in its market capitalization. The Company concluded that the fair value of the reporting unit was less than the carrying amount in excess of goodwill. As a result, during the fourth quarter of 2019 the Company recorded a $12,564,000 impairment charge, which is presented within the caption, “Loss on impairment” in the accompanying consolidated statements of operations. The Company is no longer manufacturing or selling the DenerveX device but continues to explore possible opportunities to monetize such technology.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions	Note 8 – Related Party Transactions Consulting Expense The Company entered into an oral consulting arrangement with St. Louis Family Office, LLC, controlled by Jimmy St. Louis, former CEO of RMS, in January 2019 in the amount of $10,000 per month plus benefits reimbursement for advisory services. The Company terminated this agreement effective June 30, 2019. For the year ended December 31, 2020 and December 31, 2019, the Company expensed approximately $0 and $68,000 respectively in consulting fees to St. Louis Family Office. The Company entered into a consulting agreement with Strategos Public Affairs, LLC (Strategos) on February 15, 2019 for a period of twelve months, unless otherwise terminated by giving thirty days prior written notice. A close family member of the Company’s prior CEO is a partner in Strategos. The monthly fee started at $4,500 and increased to approximately $7,500 per month. Strategos provided information to key policymakers in the legislature and executive branches of government on the benefits of the cellular therapies offered by LHI, advocated for legislation that supports policies beneficial to patient access and opposed any legislation that negatively impacts the Company’s ability to expand treatment opportunities, and position the Company and its related entities as the expert for information and testimony. The Company terminated this agreement in March 2020. For years ended December 31, 2020 and December 31, 2019 the Company expensed approximately $15,000 and $71,000, respectively. Officers and Board Members and Related Expenses On July 29, 2019, the Board appointed Dr. Andre Terzic to the Board. Dr. Andre Terzic served as a director at the Center for Regenerative Medicine of Mayo Clinic in Rochester, Minnesota for the last five years. Dr. Andre Terzic is the Chair of the Pharmaceutical Science and Clinical Pharmacology Advisory Committee of Food and Drug Administration, the President of the American Society for Clinical Pharmacology & Therapeutics, and one of the co-founders of Rion. Rion is a Minnesota Bio-tech Company focused on cutting-edge regenerative technologies. Dr. Terzic received his M.D. at University of Belgrade in Paris, France in 1985 and his Ph.D. from the Department of Pharmacology of University of Illinois in 1991. On July 30, 2019, the Board appointed Dr. Atta Behfar as a member of the Board. Dr. Atta Behfar has worked as a cardiologist at the Department of Cardiovascular Medicine of Mayo Clinic for the last five years. Dr. Atta Behfar is a Director of the Van Cleve Cardiac Regenerative Medicine program at Mayo Clinic and one of the founders of Rion. Dr. Behfar received a Bachelor of Science degree in Biochemistry from Marquette University in 1998 and a M.D. and Ph.D. from Mayo Clinic College of Medicine, Mayo Graduate School in 2006. On November 18, 2019, Dr. Andre Terzic and Dr. Atta Behfar resigned from the Company’s Board of Directors to avoid any potential conflicts that could arise from the Company’s Service Agreement with Rion, pursuant to which Rion will supply exosomes to and support FDA-regulated clinical research for the Company. Drs. Terzic and Behfar are co-founders of Rion. In connection with the April Offering, the Company’s former CEO, William Horne, entered into an amendment letter to his employment agreement which provides that his salary will be reduced to $0 per month. This agreement was amended on July 29, 2020 to provide that Mr. Horne will receive a monthly base salary of $12,500 effective on June 1, 2020 and that his base salary will increase to $20,833 per month upon the first day of the month when the Company completes a Qualified Financing. Mr. Horne agreed to continue to defer the $108,000 in base salary deferred by him in 2018 (the “Deferred Salary”) until such time as there is a positive cash flow to meet the Company’s financial obligations and then the Company and Mr. Horne will work together in good faith to negotiate a payment plan for such Deferred Salary. On September 29, 2020, Mr. William Horne resigned as the Company’s CEO and President but will remain on the Board of Directors. Effective February 1, 2019, the Company entered into an oral consulting agreement with Mr. Raymond Monteleone, Board Member and Chairman of the Audit Committee, in which Mr. Monteleone received $10,000 per month for advisory services and $5,000 per quarter as Audit Committee Chair in addition to regular quarterly board meeting fees. Effective March 25, 2020, the Company reduced the advisory services to $5,000 per month and the fees per quarter as the Audit Committee Chair and the Compensation Committee Chair to $2,500. For the year ended December 31, 2020 and December 31, 2019, the Company expensed approximately $93,000 and $125,000 in compensation and Board of Director fees to Mr. Monteleone, respectively. For the year ended December 31, 2020 and December 31, 2019, the Company expensed $12,500 and $5,000 for Board of Director fees to Michael Yurkowsky, respectively. Mr. Yurkowsky entered into an oral agreement with the Company on October 1, 2020 in which Mr. Yurkowsky will receive $4,167 per month to serve on the Board of Directors. Debt and Other Obligations The short-term related party notes as of December 31, 2019 of $1,635,000 is comprised of four loans made to the Company during 2019, by Horne Management, LLC, controlled by former CEO, William E. Horne. These were advanced for working capital purposes and had the terms as indicated below. A loan for $900,000 was made on July 25, 2019. This loan accrues interest at 5.5% and is due and payable upon demand of the creditor. A loan for $350,000 was made on September 26, 2019 with the following terms: ● 12% interest rate with a maturity date of March 26, 2020. ● The Company was unable to pay back the principal and interest by November 26, 2019; therefore, it issued to Lender a three-year warrant to purchase 400,000 shares of the Company’s common stock with a purchase price of $0.75 per share in accordance with the terms of the note. ● The Company was unable to pay back the loan on March 26, 2020, therefore, the interest rate increased to 15%. A loan for $150,000 was made on October 28, 2019 with the following terms: ● 12% interest rate with a maturity date of April 28, 2020. ● The Company was unable to pay back the principal and interest by December 28, 2019; therefore, it issued to Lender a three-year warrant to purchase 171,429 shares of the Company’s common stock with a purchase price of $0.75 per share in accordance with the terms of the note. ● If the Company is unable to pay the loan as of April 28, 2020, the interest rate increases to 15%. A loan for $235,000 was made on November 13, 2019 with the following terms: ● 12% interest rate with a maturity date of May 13, 2020. ● The Company was unable to pay back the principal and interest by January 13, 2020; therefore in January 2020 it issued to Lender a three-year warrant to purchase 268,571 shares of the Company’s common stock with a purchase price of $0.75 per share in accordance with the terms of the note. ● If the Company is unable to pay the loan as of May 13, 2020, the interest rate increases to 15%. In connection with the April Offering, Mr. Horne’s notes were extinguished for 4,368,278 common shares and 4,368,278 warrants resulting in a gain on extinguishment of approximately $1,300,000. Change in Control On September 11, 2020, with the closing of the Rights Offering, FWHC, LLC, FWHC, Bridge, LLC, and FWHC Bridge Friends, LLC (collectively known as “FWHC”) gained control of the Company by subsequently owning approximately 61% of the fully diluted shares of the Company. On July 28, 2020, the Company issued an aggregate of 15,518,111 shares of its common stock to FWHC upon the conversion of its issued Series D Convertible Preferred Stock. The Preferred Stock was converted pursuant to a mandatory conversion triggered by the majority holder of the Series D Convertible Preferred Stock as set forth in the Certificate of Designations for the Series D Convertible Preferred Stock. On September 11, 2020, with the closing of the Rights Offering, FWHC was issued 123,031,819 shares of Preferred A for conversion of the outstanding promissory notes from April 2020, 75,162,429 shares of Preferred A Stock for conversion of the April Secured Note, 35,860,079 shares of Preferred A Stock for conversion of the Hawes Notes, and 117,362,143 shares of Preferred A Stock issued at upon the closing Rights Offering. FWHC was also issued 273,356,676 10-year warrants at $0.014 upon the closing of the Rights Offering.

Equity Transactions

Equity Transactions	12 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Equity Transactions	Note 9 - Equity Transactions For the consolidated statement of stockholders’ deficit as of January 1, 2019, the common stock, preferred stock and additional paid in capital reflect the accounting for the stock received by the RMS members as of the Merger as if it was received as of that date and the historical accumulated deficit of RMS. As of the closing of the Merger, before the contingent additional exchange shares impact from the sale of new securities, the stock received by RMS was 33,661 shares of Series C Preferred Stock, which was later converted into approximately 33,661,000 shares of common stock, with common stock par value of approximately $33,700 and additional paid-in capital of approximately $3,566,000. The historical accumulated deficit and non-controlling interest of RMS as of the closing was approximately $9,296,000 and $370,000, respectively. Rights Offering The Company established July 28, 2020 as the Record Date for purposes of establishing a date for the Company’s Rights Offering whereby each holder of the Company’s Common stock on the Record Date will be entitled to three subscription rights, each to purchase one share of Series A Preferred Stock. As mentioned below, the Company entered into a standby purchase agreement with certain creditors who had previously purchased secured convertible notes and warrants, pursuant to which such creditors agreed (a) not to exercise any subscription rights they may receive as stockholders of the Company in the registered rights offering (described below) and (b) instead to purchase any Series A Preferred Stock corresponding to the unexercised rights in the rights offering up to an aggregate amount of approximately $2.8 million at the same subscription price. The amounts due under the standby purchase agreements became calculable and payable upon the expiration of the rights offering as set forth below. On September 11, 2020, the registered rights offering (Registration No. 333-239629) of the Company expired. Pursuant to the Rights Offering, on September 24, 2020, the Company issued (i) 15,235,381 shares of its Series A Preferred Stock at a price of $0.014 per share to holders of its common stock who validly exercised their subscription rights prior to the expiration time and (ii) 203,049,643 shares of its Series A Preferred Stock to the standby purchasers as part of the standby commitment. A total of 218,285,024 shares of Series A Preferred Stock were issued during the Rights Offering. The Rights Offering, including the standby component, resulted in gross proceeds to the Company of $3,055,985 excluding issuance costs of approximately $320,000. While the Rights Offering expired on September 11, 2020, it was not consummated until September 24, 2020 while logistical closing conditions including the calculation and clearance of funds were being processed. Common Stock Issuance On January 8, 2019, the Company entered into a securities purchase agreement (the “SPA”) with four purchasers (the “Purchasers”) pursuant to which the four Purchasers invested in the Company an aggregate amount of $2,000,000, with $1,800,000 in cash and $200,000 by cancellation of debt as explained below, in exchange for forty units (the “Units”), each consisting of a convertible note (the “Convertible Note”) with the principal amount of $50,000 and a warrant (the “Warrant”) to purchase common stock (the “common stock”) of the Company at a purchase price of $0.75 per share. For further discussion of the SPA, refer to Note 9 - “Equity Transactions” to the consolidated financial statements in the Company’s 2019 Annual Report on Form 10-K is incorporated by reference herein. The Company entered into other SPA’s with additional purchasers, which brought the aggregate amount of capital raised in all these offerings to $7,000,000, as of April 5, 2019, excluding the shares issued for conversion of short-term debt, discussed below. As a result of the sales of new securities of at least $5,650,000, the Company issued an additional 17,264 Series C Preferred Stock to RMS members in accordance with the provisions of the APA in the first quarter of 2019. These shares automatically converted to 17,263,889 shares of common stock. All the Convertible Notes from the SPA, as well as the shares of Series C Preferred Stock issued to RMS members, were automatically converted into shares of common stock at closing on January 8, 2019. In February 2019, 250,000 shares of common stock were issued pursuant to conversion of short-term debt and accrued interest. In March 2019, the Company issued an aggregate of 130,085 shares of common stock at $0.40 per share for consulting fees in an amount equivalent to $52,033. In August 2019, the Company issued 150,000 shares of common stock to consultants in consideration of consulting services rendered to the Company. At the time of issuance, the fair market value of the shares was $0.29, and, as a result, $43,500 was expensed for the year ending December 31, 2019. On April 25, 2019, the Company issued 4,225,634 shares of common stock valued at $0.40 per share to Mr. William E. Horne, the Company’s former CEO, in a restricted stock award which was 100% vested when issued. The Company recognized approximately $1,690,000 of compensation expense during the year ended December 31, 2019 related to the restricted stock award. This restricted stock award was issued pursuant to his employment agreement with the Company, which stated that this restricted stock award (as well as the incentive stock options issued in the quarter ended March 31, 2019) would be fully vested if not issued within fifteen days of the Merger. Neither award was issued within that time frame and both awards became fully vested when issued. The aggregate number of shares of common stock from these two awards is 4,475,634 and was calculated based on 7% of the Company’s issued and outstanding common stock as of the closing of the Merger. During the year ended December 31, 2019, 715,279 shares were issued pursuant to conversions of 2,650 shares of Series B Convertible Preferred Stock and 50,367 shares for accrued dividends thereunder. In conjunction with the Series D Preferred financing (See Note 14), the Company offered the Series B warrant holders the option to exchange their warrants on the basis of 1 warrant for 0.40 common shares. Warrant holders chose to exchange 1,007,813 warrants with a fair value of approximately $75,000 for 403,125 shares of common stock in 2019. The Series B Warrants were adjusted to fair value on the date of the exchange with the change in fair value being recorded in earnings. The fair value of the common stock issued was $73,000 which approximated the fair value of the Series B Warrants exchanged. In February 2020, the Company issued LilyCon Investments $35,000 in shares of the Company’s common stock at a weighted average share price of $0.32 per share for a total of 109,375 shares per the terms of the consulting agreement executed in February 2019. On April 23, 2020, Horne Management, LLC agreed to convert its notes plus accrued interest into (i) 4,368,278 shares of common stock of the Company and (ii) a ten-year warrant to purchase up to an equivalent number of shares of the Company’s common stock with such conversion to be effective as of April 17, 2020. This warrant will have an exercise price equal to the price per share at which securities were offered to investors for purchase at the Rights Offering, which was $0.014, and is exercisable beginning on the day immediately following the closing of the Rights Offering. On July 28, 2020, the Company issued an aggregate of 17,893,076 shares of its common stock upon the conversion of all of its issued and outstanding Series B and Series D Convertible Preferred Stock. The Series B and D Convertible Preferred Stock was converted pursuant to a mandatory conversion triggered by the majority holder of the Series D Convertible Preferred Stock as set forth in the Certificate of Designations for the Series D Convertible Preferred Stock. On July 29, 2020, the Company filed its Second Amended and Restated Certificate of Incorporation (the “Amended COI”). The Amended COI provides for the issuance of up 1,600,000,000 shares of Common Stock and 1,000,000,000 shares of Preferred Stock, of which 800,000,000 shares are designated as Series A Preferred Stock and eliminates the previously authorized classes of preferred stock. The Amended COI also delineates the rights of the Series A Preferred Stock. On September 11, 2020, 1,000,000 warrants were converted to common stock upon the closing of the Rights Offering for a certain warrant holder. For the year ended December 31, 2020, 4,020,031 Series A Preferred Stock were converted to common stock at the request of certain Rights Offering participants. Series A Preferred Stock On September 11, 2020, the registered Rights Offering (Registration No. 333-239629) of the Company expired. Pursuant to the Rights Offering, on September 24, 2020, the Company issued (i) 15,235,381 shares of its Series A preferred stock at a price of $0.014 per share to holders of its common stock who validly exercised their subscription rights prior to the expiration time and (ii) 203,049,643 shares of its Series A preferred stock to the standby purchasers as part of the standby commitment. The rights offering, including the standby component, resulted in gross proceeds to the Company of $3,055,985. While the rights offering expired on September 11, 2020, it was not consummated until September 24, 2020 while logistical closing conditions including the calculation and clearance of funds were being processed. Additionally, on September 24, 2020, the Company issued an aggregate of 323,844,416 shares of its Series A Preferred Stock to the holders of outstanding promissory notes, issued in April 2020, in the aggregate principal amount and accrued interest of $4,483,617. Included in this issuance, FWHC was issued 123,031,819 shares of Preferred A for conversion of the outstanding promissory notes from April 2020, 75,162,429 shares of Preferred A Stock for conversion of the April Secured Note and 35,860,079 shares of Preferred A Stock for conversion of the Hawes Notes (see Note 11). The notes were converted pursuant to a mandatory conversion triggered by the completion of the rights offering. Such shares were issued under an exemption from registration in reliance on Section 3(a)(9) of the Securities Act. The original notes were issued in reliance on Section 4(a)(2) of the Securities Act. Voting Rights Holders of Series A Preferred Stock (“Series A Holders”) have the right to receive notice of any meeting of holders of common stock or Series A Preferred Stock and to vote upon any matter submitted to a vote of the holders of common stock or Series A Preferred Stock. Each Series A Holder shall vote on each matter submitted to them with the holders of common stock. Conversion Series A Preferred Stock converts to common stock at a 1:1 ratio immediately upon request of the Series A Holder. Liquidation Series A Preferred Stock does not have preferential treatment over common stock shareholders if the Company liquidates or dissolves. Series B Convertible Preferred Stock Voting Rights Holders of Series B Convertible Preferred Stock (“Series B Holders”) have the right to receive notice of any meeting of holders of common stock or Series B Preferred Stock and to vote upon any matter submitted to a vote of the holders of common stock or Series B Preferred Stock. Each Series B Holder shall vote on each matter submitted to them with the holders of common stock. Liquidation Upon the liquidation or dissolution of the business of the Company, whether voluntary or involuntary, each Series B Holder shall be entitled to receive, for each share thereof, out of assets of the Company legally available therefore, a preferential amount in cash equal to the stated value plus all accrued and unpaid dividends. All preferential amounts to be paid to the Series B Holders in connection with such liquidation, dissolution or winding up shall be paid before the payment or setting apart for payment of any amount for, or the distribution of any assets of the Company to the holders of the Company’s common stock but after the Series D Holders receive their respective liquidation value. The Company accrues these dividends as they are earned each period. On January 8, 2019, the Company completed the issuance of Convertible Notes with a conversion price of $0.40. As a result, the exercise price on all of the warrants issued with the Series B Convertible Preferred Stock was adjusted downward to $0.36. In the first quarter of 2019, the Company recognized a beneficial conversion feature related to the Series B Preferred Stock of approximately $33,000, which was credited to additional paid-in capital, and reduced the income available to common shareholders. Since the Series B Preferred Stock can immediately be converted by the holder, the beneficial conversion feature was immediately accreted and recognized as a deemed dividend to the preferred shareholders. Series B and Series D Convertible Preferred Stock Conversions and Repurchase During the year ended December 31, 2019, 9,250 shares of Series B Convertible Preferred Stock, par value $0.001, and accrued dividends were assumed with the Merger and an aggregate of 2,650 shares of Series B Convertible Preferred Stock, and accrued dividends, were subsequently converted into an aggregate of 715,279 shares of the Company’s common stock. On July 28, 2020, the Company issued an aggregate of 17,893,076 shares of its common stock upon the conversion of all of its issued and outstanding Series B and Series D Convertible Preferred Stock (the “Preferred Stock”). The Preferred Stock was converted pursuant to a mandatory conversion triggered by the majority holder of the Series D Convertible Preferred Stock as set forth in the Certificate of Designations for the Series D Convertible Preferred Stock. As of December 31, 2020, the Company does not have any Series B or Series D Convertible Preferred Stock outstanding. Debt Conversion Convertible Notes and Promissory Note to Related Party The $750,000 convertible notes payable assumed in the Merger had a fair value of approximately $598,000 on the acquisition date. Subsequently, on February 6, 2019, $100,000 of the outstanding Convertible Notes was converted into an aggregate of 250,000 shares of common stock, eliminating $100,000 of the Company’s debt obligation. The debt was converted into shares of common stock at $0.40 per share, in accordance with the SPA (see Note 11). On September 24, 2020, the Company issued an aggregate of 323,844,416 shares of its Series A Preferred Stock to the holders of outstanding promissory notes, issued in April 2020, in the aggregate principal amount and accrued interest of $4,483,617. Included in this issuance, FWHC was issued 123,031,819 shares of Preferred A for conversion of the outstanding promissory notes from April 2020, 75,162,429 shares of Preferred A Stock for conversion of the April Secured Note and 35,860,079 shares of Preferred A Stock for conversion of the Hawes Notes (see Note 11). The notes were converted pursuant to a mandatory conversion triggered by the completion of the Rights Offering. Stock-Based Compensation Plan The Company utilizes the Black-Scholes valuation method to recognize stock-based compensation expense over the vesting period. The expected life represents the period that the stock-based compensation awards are expected to be outstanding. Stock Option Activity For the years ended December 31, 2020 and 2019, the Company recognized approximately $1,000 and $95,000 of stock option expense, respectively. The expense for the year ended December 31, 2019 is primarily related to an option to purchase 250,000 shares of the Company’s common stock that was issued to the Company’s former CEO, William E. Horne, pursuant to his employment agreement. These options were immediately vested upon issuance. As of December 31, 2020, all outstanding stock options were fully vested, and related compensation expense recognized. The following is a summary of stock option activity for the years ending December 31, 2020 and 2019: Shares Weighted Average Exercise Price Weighted Average Remaining Term (Years) Outstanding at December 31, 2018 — — — Assumed with the RMS merger transaction 557,282 $ 2.78 6.06 Granted 250,000 0.40 9.02 Expired/Cancelled (382,282 ) 2.86 — Outstanding at December 31, 2019 425,000 $ 1.38 7.71 Granted — — — Expired/Cancelled (15,000 ) 1.35 — Outstanding and exercisable at December 31, 2020 410,000 $ 1.39 6.72 Non-Controlling Interest For the years ended December 31, 2020 and 2019, the Company consolidated the results for LI Dallas, LI Nashville, LI Pittsburgh and LI Scottsdale as VIEs. The Company owns no portion of any of these four entities which own their respective clinics; however, the Company maintains control through their management role for each of the clinics, in accordance with each clinic’s respective management agreement. Based on these agreements, the Company has the responsibility to oversee and make decisions on behalf of the clinics, except for medical care and procedures. Beginning in January 2018, the Company adopted the policy for all of the VIEs that the management fee charged by the Company would equal the amount of net income from each VIE on a monthly basis, bringing the amount of the net income each month for each VIE to a net of zero. Due to this policy, there was no change in the non-controlling interest for the years ended December 31, 2020 or 2019 related to the net income (loss) as it was $0 each month through the management fee charged by the Company. Net Loss Per Share Basic loss per share is computed on the basis of the weighted average number of shares outstanding for the reporting period. Diluted loss per share is computed on the basis of the weighted average number of common shares plus dilutive potential common shares outstanding using the treasury stock method. Any potentially dilutive securities are antidilutive due to the Company’s net losses. As of December 31, 2020, the Company had 538,109,409 shares outstanding of Series A Preferred Stock which converts on a 1:1 ratio to common stock and would be considered dilutive upon conversion. There is no difference between the basic and diluted net loss per share when including 23,937,765 warrants (exercise price of $0.016 and higher) and 410,000 common stock options that are outstanding as they are considered anti-dilutive and excluded for the year ended December 31, 2020 due to the net loss. This does not consider 387,126,145 warrants outstanding at December 31, 2020 as their exercise price is below the current stock price. For the year ended December 31, 2019, there was no difference between the basic and diluted net loss per share: 44,806,076 warrants and 425,000 common stock options outstanding were considered anti-dilutive and were excluded.

Commitments & Contingencies

Commitments & Contingencies	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments & Contingencies	Note 10 – Commitments & Contingencies Consulting Agreements The Company entered into an agreement with Jesse Crowne, a former Director and Co-Chairman of the Board of the Company, to provide business development consulting services for a fee of $5,000 per month. Additionally, 62,500 shares of common stock at $0.29 per share was issued in connection with a separate agreement on August 29, 2019. The Company incurred expense of approximately $10,000 and $83,000 for the years ended December 31, 2020 and 2019, respectively, related to these agreements. The Company entered into a consulting agreement with LilyCon Investments, LLC effective February 1, 2019 for services related to evaluation and negotiation of future acquisitions, joint ventures, and site evaluations/lease considerations. The duration of the consulting agreement is for a period of twelve months in the amount of $12,500 per month with a $15,000 signing bonus. Either party may terminate this agreement with or without cause upon 30 days written notice. The agreement also provides LilyCon Investments with $35,000 in stock (to be calculated using an annual variable weighted average price from February 2019 through January 2020) to be granted on the one-year anniversary of this agreement, if the agreement has not been terminated prior to that date. For years ended December 31, 2020 and 2019, the Company expensed a total of approximately $65,000 and $153,000, respectively, in compensation to LilyCon Investments. In February 2020, the Company issued LilyCon Investments $35,000 in shares of H-CYTE stock at an average share price of $0.31 per share for a total of 106,061 shares per the terms of the agreement. In March 2020, this agreement was modified to lower the monthly payment amount to $5,000. This agreement was terminated effective April 1, 2020. The Company entered into a consulting agreement with Goldin Solutions, effective August 4, 2019, for media engagement and related efforts, including both proactive public relations and crisis management services. The agreement has a minimum term of six months, with a $34,650 monthly fee plus expenses payable each month, with the exception of a first month discount of $12,600. For year ended December 31, 2020 and December 31, 2019, the Company expensed $99,000 and $162,000, respectively. The Company terminated this agreement in March 2020. The Company entered into a consulting agreement with Tanya Rhodes of Rhodes & Associates, Inc, effective June 15, 2020, to serve as the Chief Technology Officer (Research) of the Company. The agreement has a minimum term of six months with an average fee of $20,000 per month plus expenses which increases 5% per month on January 1 of each calendar year unless an alternative retainer amount is negotiated and agreed upon by both parties. The Company extended the contract on January 1, 2021, resulting in monthly expenses of $22,500 plus expenses for services rendered. Litigation From time to time, the Company may be involved in routine legal proceedings, as well as demands, claims and threatened litigation that arise in the normal course of our business. The ultimate amount of liability, if any, for any claims of any type (either alone or in the aggregate) may materially and adversely affect the Company’s financial condition, results of operations and liquidity. In addition, the ultimate outcome of any litigation is uncertain. Any outcome, whether favorable or unfavorable, may materially and adversely affect the Company due to legal costs and expenses, diversion of management attention and other factors. The Company expenses legal costs in the period incurred. The Company cannot assure that additional contingencies of a legal nature or contingencies having legal aspects will not be asserted against the Company in the future, and these matters could relate to prior, current or future transactions or events. As of December 31, 2020, the Company had no litigation matters in which the Company believes require any accrual or disclosure. Guarantee The Company has guaranteed payments based upon the terms found in the management services agreements to affiliated physicians related to LI Dallas, LI Nashville, LI Pittsburgh, LI Scottsdale, and LI Tampa. For the years ending December 31, 2020 and 2019 payments totaling approximately $36,000 and $141,000, respectively, were made to these physicians’ legal entities. Due to the Company ceasing operations effective March 23, 2020 in LI Dallas, LI Pittsburgh, LI Scottsdale, and LI Tampa, the guaranteed payments for these clinics were suspended due to COVID-19 in March 2020. The Company will resume these guaranteed payments in April 2021. Rion Agreements On June 21, 2019, H-CYTE entered into an exclusive product supply agreement with Rion, LLC (“Rion”) to develop and distribute (post FDA approval) a biologic for chronic obstructive pulmonary disease (“COPD”), the fourth leading cause of death in the U.S. Rion has established a novel biologics technology to harness the healing power of the body. Rion’s innovative technology, based on science developed at Mayo Clinic, provides an off-the-shelf platform to enhance healing in soft tissue, musculoskeletal, cardiovascular and neurological organ systems. This agreement provides for a 10-year exclusive and extendable supply agreement with Rion to enable H-CYTE to develop proprietary biologics. On October 9, 2019, the Company entered into a services agreement with Rion which provides the Company the benefit of Rion’s resources and expertise for the limited purpose of (i) consulting with and assisting H-CYTE in the further research and development for the generation of a new biologic and (ii) subsequently assisting H-CYTE in seeking and obtaining FDA Phase 1 IND clearance for this biologic as necessary. Rion also agrees to consult with H-CYTE in its arrangement for services from third parties unaffiliated with Rion to support research, development, regulatory approval, and commercialization of the biologic. With these agreements, Rion will serve as the product supplier and contracted preclinical development arm of the biologic. H-CYTE will control the commercial development and the clinical trial investigation. After conducting the clinical efficacy trials of this biologic, H-CYTE intends to pursue submission of a Biologics License Application (“BLA”) for review by the FDA for treatment of COPD. An additional $350,000 in expense is expected to be incurred per the Rion agreements. At this time, the Company is not able to estimate when this expense will occur. The Company has recorded research and development expense of $1,150,000 and $0 related to Rion, for the years ended December 31, 2020 and 2019, respectively.

Debt

Debt	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Debt	Note 11 – Debt Convertible note The Convertible Notes payable represents a securities purchase agreement with select accredited investors, which was assumed in the Merger. The debt assumed by the Company consisted of $750,000 of units (the “Units”) with a purchase price of $50,000 per Unit. Each Unit consists of (i) a 12% senior secured convertible note, initially convertible into shares of the Company’s common stock, par value $0.001 per share, at a conversion price equal to the lesser of $0.40 or ninety percent (90%) of the per share purchase price of any shares of common stock or common stock equivalents issued in future private placements of equity and/or debt securities completed by the Company following this offering, and (ii) a three-year warrant to purchase such number of shares of the Company’s common stock equal to one hundred percent (100%) of the number of shares of common stock issuable upon conversion of the notes at $0.40. The Warrants were initially exercisable at a price equal to the lesser of $0.75 or ninety percent (90%) of the per share purchase price of any shares of common stock or common stock equivalents issued in future private placements of the debt and/or equity securities completed by the Company following the issuance of warrants. The Convertible Notes are secured by all of the assets of the Company. The Convertible Notes sold in the offering were initially convertible into an aggregate of 1,875,000 shares of common stock. The down round feature was triggered on January 8, 2019, and the conversion price of the Convertible Notes was adjusted to $0.36. The Company recognized the down round as a deemed dividend of approximately $288,000 which reduced the income available to common stockholders. On February 6, 2019, $100,000 of the Company’s $750,000 outstanding Convertible Notes, plus accrued interest, was converted into an aggregate of 251,667 shares of common stock, eliminating $100,000 of the Company’s debt obligation. The debt was converted into shares at $0.36 per share, which was the conversion price per the SPA subsequent to the trigger of the down round feature. In 2019, the Company redeemed $350,000 of convertible notes payable in principal and $52,033 in interest payable for three of the noteholders. The Company reached an extension with the remaining noteholder, George Hawes, which extended the maturity date of the Hawes Notes for one year, until September 30, 2020. The notes had a principal balance of $300,000 plus penalties of approximately $85,000 and accrued interest of approximately $40,000 for a total adjusted principal balance upon the September 30, 2019 extension of $424,615. In connection with the April Offering, the Company entered into an amendment with the Investor with respect to the outstanding 12% Senior Secured Convertible Note due September 30, 2020. The Hawes Notes were purchased by the Investor from its original holder, George Hawes, on March 27, 2020. The Hawes Notes had a principal balance of $424,615 as of December 31, 2019. The amendment to the Hawes Notes among other things, eliminates the requirement that the Company make monthly payments of accrued interest. The Company determined the proper classification of the amendment based on ASC 470-50, Debt Modifications and Extinguishments. Because the change in the present value of cash flows of the modified debt was less than 10% when compared to the present value of the cash flows of the original debt, extinguishment accounting did not apply. The effective interest rate was reassessed resulting in an effective interest rate of 11.90% and interest expense as of September 30, 2020, of approximately $10,000. The Company converted the Hawes Notes plus accrued interest into 35,860,079 shares of Preferred A shares on September 11, 2020, upon the closing of the Rights Offering. Notes Payable Notes payable were assumed in the Merger and are due in aggregate monthly installments of approximately $5,800 and carry an interest rate of 5%. Each note originally had a maturity date of August 1, 2019. The Company finalized an eighteen-month extension to March 1, 2021. The promissory notes have an aggregate outstanding balance of approximately $67,000 and $78,000 at December 31, 2020 and December 31, 2019. The Company has not made payments on this note since February 10, 2020, due to COVID-19, resulting in accrued interest of approximately $1,900. The short-term notes with related party were issued by the Company during 2019, and as of March 31, 2020 consisted of four loans totaling $1,635,000, made to the Company by Horne Management, LLC, controlled by former CEO, William E. Horne for working capital purposes. The loans bore interest rates ranging from 5.5% to 12%, in some cases increasing to 15% if not paid by the respective maturity date ranging from March 26, 2020 to May 13, 2020. Some of these loans provided for the issuance of warrants at 114% warrant coverage if the loan was not repaid within two months. None of these loans were repaid and 840,000 warrants were issued at an exercise price of $0.75 per share in the fourth quarter of 2019 and the first quarter of 2020. On April 23, 2020, Horne Management, LLC agreed to convert the related notes plus accrued interest into (i) 4,368,278 shares of common stock of the Company and (ii) a ten-year warrant to purchase up to an equivalent number of shares of the Company’s common stock with such conversion to be effective as of April 17, 2020. This warrant will have an exercise price equal to the price per share at which securities were offered to investors for purchase at the Rights Offering totaling $0.014 and is exercisable beginning on the day immediately following the earlier to occur of (x) the closing of the Rights Offering and (y) November 1, 2020. The Rights Offering closed on September 11, 2020. On the date of the transaction, the carrying amount of the note and accrued interest was approximately $1,717,000. The fair value of the Common Stock was valued based on the trading market price on the date of the transaction and the warrants were valued using a Lattice model. The fair value of the Common Stock and warrants issued in the transaction was approximately $218,000 and $199,000, respectively. Since the fair value of the common stock and warrants was less than the carrying amount of the note, the Company recorded a gain on extinguishment of the debt of approximately $1,300,000. On March 27, 2020, the Company issued a demand note (the “Note”) in the principal amount of $500,000 to FWHC Bridge, LLC (the “Investor”) in exchange for a loan made by the Investor in such amount to cover the Company’s working capital needs. Subsequently on April 9, 2020, in exchange for an additional loan of $500,000 made by the Investor to the Company, the Company amended and restated the Note to reflect a new principal amount of $1,000,000 (the “April Secured Note”). The April Secured Note bears simple interest at a rate of 12% per annum. The Investor is an affiliate of FWHC Holdings, LLC, a pre-existing shareholder of the Company, which served as lead investor in the Company’s recent Series D Convertible Preferred Stock Offering. On September 24, 2020, the Company issued an aggregate of 323,844,416 shares of its Series A Preferred Stock to the holders of outstanding promissory notes, issued in April 2020, in the aggregate principal amount and accrued interest of $4,483,618. Included in this issuance, FWHC was issued 123,031,819 shares of Preferred A for conversion of the outstanding promissory notes from April 2020, 75,162,429 shares of Preferred A Stock for conversion of the April Secured Note and 35,860,079 shares of Preferred A Stock for conversion of the Hawes Notes (see Note 11). The notes were converted pursuant to a mandatory conversion triggered by the completion of the Rights Offering. All notes payable, except the promissory note having an outstanding balance of $67,000, were extinguished during the year ended December 31, 2020. Paycheck Protection Program On April 29, 2020, the Company issued a promissory note in the principal amount of $809,082 to the Bank of Tampa in connection with a loan in such amount made under the Paycheck Protection Program (“PPP Loan”). The PPP Loan bears interest at a rate of 1% per annum and is payable in eighteen monthly payments of $45,533 beginning on approximately August 14, 2021. The Company elected to use a 24-week Covered Period, per the SBA Paycheck Protection Program guidelines, the Covered Period ended on October 14, 2020. The Company can apply for loan forgiveness in an amount equal to the sum of the following costs incurred by the Company: 1) payroll costs; 2) any payment of interest on covered mortgage obligations; 3) any payment on a covered rent obligation; and 4) any covered utility payment The amount forgiven will be calculated (and may be reduced) in accordance with the Paycheck Protection Program criteria set by the SBA. Not more than 40% of the amount forgiven can be attributed to non-payroll costs, as listed above. As long as a borrower submits its loan forgiveness application within ten months of the completion of the Covered Period (as defined below), the borrower is not required to make any payments until the forgiveness amount is remitted to the lender by SBA. If the loan is fully forgiven, the borrower is not responsible for any payments. If only a portion of the loan is forgiven, or if the forgiveness application is denied, any remaining balance due on the loan must be repaid by the borrower on or before the maturity date of the loan. Interest accrues during the time between the disbursement of the loan and SBA remittance of the forgiveness amount. The borrower is responsible for paying the accrued interest on any amount of the loan that is not forgiven. The lender is responsible for notifying the borrower of remittance by SBA of the loan forgiveness amount (or that SBA determined that no amount of the loan is eligible for forgiveness) and the date on which the borrower’s first payment is due, if applicable. The Company plans on filing its forgiveness application in early 2021. The Company believes a majority of the PPP loan will be forgiven.

Derivative Liability - Warrants

Derivative Liability - Warrants and Redemption Put	12 Months Ended
	Dec. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Liability - Warrants and Redemption Put	Note 12 – Derivative Liability – Warrants And Redemption Put The Company’s derivative liabilities are classified within Level 3 of the fair value hierarchy because certain unobservable inputs were used in the valuation models. These assumptions included estimated future stock prices, potential down-round financings for the Warrants, and potential redemptions for the Redemption Put Liability. The following is a reconciliation of the beginning and ending balances for the liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the year ended December 31, 2020: Derivative Liability - Warrants Beginning balance as of December 31, 2018 $ — January 8, 2019 – date of dilutive financing 1,215,678 Exchange for common stock (72,563 ) Fair value adjustments (827,260 ) Balance at December 31, 2019 315,855 Series D Warrant reclass from equity to liability classification 509,764 Warrants issued with modification of Horne Management Notes 198,994 Warrants issued with April 17, 2020 financing 6,148,816 Fair value adjustments (2,986,853 ) Warrant reclassification from liability to equity classification (4,186,576 ) Balance at December 31, 2020 $ — Redemption Put Liability Beginning balance as of December 31, 2018 $ — November 15, 2019 – date of issuance 614,095 Fair value adjustments (346,696 ) Balance at December 31, 2019 $ 267,399 Issuance of Series D Convertible Preferred Stock 5,305 Fair value adjustments (272,704 ) Balance at December 31, 2020 $ — (1) The Company did not have any assets or liabilities measured at fair value using Level 1 or 2 of the fair value hierarchy as of December 31, 2020 and December 31, 2019. (2) Upon the closing of the Rights Offering on September 11, 2020, the Derivative Liability- Warrants was no longer applicable, and its fair value was reclassed to stockholder’s equity. (3) The Series D Convertible Preferred Stock was converted into common stock on July 28, 2020 at which time the Redemption Put Liability was no longer applicable, and its fair value was adjusted to zero and the extinguishment was recorded to income. Derivative Liability- Warrants Series B Warrants In connection with the securities purchase agreements executed in May 2018 (which the Company assumed in the Merger), whereby 108,250 shares of the Company’s Series B Convertible Preferred Stock (the “Series B Shares”) and warrants were issued to purchase 2,312,500 shares of the Company’s common stock (“Series B Warrants”). The Series B Warrants had a three-year term at an exercise price of $0.75. The Series B Warrants contain two features such that in the event of a downward price adjustment the Company is required to reduce the strike price of the existing warrants (first feature or “down round”) and issue additional warrants to the award holders such that the aggregate exercise price after taking into account the adjustment, will equal the aggregate exercise price prior to such adjustment (second feature or “anti-dilution”). On January 8, 2019, the Company issued equity securities which triggered the down round and anti-dilution warrant features. As a result, the exercise price of the warrants was lowered from $0.75 to $0.40 and 2,023,438 additional warrants were issued. The inclusion of the anti-dilution feature caused the warrants to be accounted for as liabilities in accordance with ASC Topic 815. The fair market value of the warrants of approximately $1,200,000 was recorded as a derivative liability as a measurement period adjustment to the purchase price allocation in the third quarter of 2019. As part of the April 2020 offering, the majority holders of the Series B Warrants agreed to terminate all anti-dilution price protection in their warrants and adjusted the exercise price to equal the price per share at which shares of preferred stock are offered for purchase in the Rights Offering. The Company issued an additional 296,875 warrants to a certain Series B holder as compensation to terminate their anti-dilution price protection. The Company also issued 1,292,411 warrants to a certain Series B holder who was non-responsive in the Company’s request to terminate their anti-dilution price protection. The modification resulted in an increase of approximately $71,000 to the fair value of the derivative liability related to the Series B Warrants. In addition, the Company recorded a change in fair market value of approximately $317,000 to the fair value of the derivative liability before the reclass to equity. Upon the closing of the Rights Offering, which occurred on September 11, 2020, the exercise price of the Series B Warrants became fixed at $0.014 and the warrants then met the conditions for equity classification. Consequently, they were revalued as of the date of the Rights Offering using a Lattice valuation technique with the following assumptions: Trading market price- $0.027, estimated exercise price- $0.014, volatility- 222%-260%, risk free rate- 0.12%-0.13% and an estimated remaining term ranging from 0.7 to 1.33 years. The fair value of the Series B Warrants totaling $73,805 was then reclassed from a derivative liability to stockholders’ equity. Series D Warrants In conjunction with the Series D Preferred Financing, the Company originally issued Series D warrants to purchase 14,944,753 shares of Common Stock with an exercise price of $0.75 per share. At inception, the Series D warrants met all the criteria to be classified as equity. As part of the April Offering, the exercise price of the Series D Warrants was reduced to the price per share at which shares of preferred stock are offered for purchase in the Offering. The modification of the exercise price resulted in the warrants requiring liability classification. The Series D Warrants were measured at fair value before and after the modification, resulting in a fair market value of approximately $510,000 when the warrants were reclassified to a liability on July 28, 2020. Upon the closing of the Rights Offering, which occurred on September 11, 2020, the exercise price of the Series D Warrants became fixed at $0.014 and the warrants then met the conditions for equity classification. Consequently, the Series D Warrants were revalued as of the date of the Rights Offering using a Lattice valuation technique with the following assumptions: Trading market price- $0.027, estimated exercise price- $0.014, volatility- 111%, risk free rate- 0.67% and an estimated term of 9.2 years. The fair value of the Series D Warrants totaling $337,400 was then reclassed from a derivative liability to stockholders’ equity. Horne Warrants On April 23, 2020, Horne Management, LLC agreed to convert the related notes plus accrued interest into (i) 4,368,278 shares of common stock of the Company and (ii) a ten-year warrant to purchase up to an equivalent number of shares of the Company’s common stock with such conversion to be effective as of April 17, 2020. The warrant will have an exercise price equal to the price per share at which securities are offered to investors for purchase at the Qualified Financing. The revised exercise price caused the warrants to require liability classification at fair value and the warrants were valued using a Lattice model with the following assumptions: Trading market price- $0.05, estimated exercise price- $0.014, volatility- 101%, risk free rate- 0.65% and an estimated term of 10 years. At inception, the estimated fair value of the Horne Warrants was approximately $199,000. Upon the closing of the Rights Offering, which occurred on September 11, 2020, the exercise price of the Horne Warrants became fixed at $0.014 and the warrants then met the conditions for equity classification. Consequently, the Horne Warrants were revalued as of the date of the Qualified Financing using a Lattice valuation technique with the following assumptions: Trading market price- $0.027, estimated exercise price- $0.014, volatility- 103%, risk free rate- 0.67% and an estimated term of 10 years. The fair value of the Horne Warrants totaling $107,123 was then reclassed from a derivative liability to stockholders’ equity. April Bridge Loan and Converted Advance Warrants The April Offering entitled the investors to warrants with the right to purchase up to 100% of the aggregate number of shares of Common Stock into which the Purchaser’s Note may ultimately be converted. The Company also received a $1,000,000 advance which was converted into the April Secured Note and April Secured Note Warrants in April 2020. The April Secured Note Warrants entitle the holder to purchase up to 200% of the aggregate number of shares of Common Stock into which the April Secured Note may ultimately be converted. The Company received an aggregate of $2,842,695 in gross proceeds through the April Offering and an advance of $1,000,000 from the April Secured Note. The Company expected the price per share at which securities would be offered for purchase in the Rights Offering to be $0.014 resulting in the assumption there would be approximately 203,050,000 and 142,857,000 shares issuable upon exercise of the Purchaser Warrants and the April Secured Note Warrants, respectively. The warrants were valued using a Lattice model with the following assumptions: Trading market price- $0.05, estimated exercise price- $0.014, volatility- 103%, risk free rate- 0.65% and an estimated term of 10 years. At inception, the estimated fair value of the Purchaser Warrants and the April Secured Note Warrants was approximately $3,279,000 and $2,869,000, respectively for a total of approximately $6,149,000. Upon the closing of the Rights Offering which occurred on September 11, 2020, the exercise price of the Purchaser and April Secured Note Warrants became fixed at $0.014 and the Company then had sufficient authorized and unissued shares available to satisfy all their commitments under their equity-linked contracts. There are 212,821,929 and 150,324,857 shares issuable upon exercise of the Purchaser and the April Secured Note Warrants, respectively for a total of 363,146,786 warrants. The Warrants were revalued as of the date of the Rights Offering using a Lattice valuation technique with the following assumptions: Trading market price- $0.027, estimated exercise price- $0.014, volatility- 107%, risk free rate- 0.67% and an estimated term of 10 years. The fair value of the Warrants of $3,668,247 was then reclassed from a derivative liability to stockholders’ equity. When the Company entered into the April Offering and revised the exercise price of the warrants to the price per share at which shares of preferred stock are offered for purchase in the Rights Offering, they no longer had sufficient authorized and unissued shares available to satisfy all their commitments to issue shares under their equity-linked contracts. The Company has adopted the sequencing approach based on the earliest issuance date. Therefore, warrants issued before the April Offering did not require liability classification, while Warrants issued with the April financing, or subsequently, will be classified as liabilities until such time the Company has sufficient authorized shares. The derivative liability - warrants has been remeasured as a change in fair value, of approximately $2,987,000 and $827,000 has been recorded as a component of other income in the Company’s consolidated statement of operations for the years ended December 31, 2020 and 2019, respectively. The fair value of the derivative liability included on the consolidated balance sheets was approximately $0 and $316,000 as of December 31, 2020 and 2019, respectively. In conjunction with the Series D Preferred financing in 2019 (See Note 14), the Company offered the Series B warrant holders the option to exchange their warrants on the basis of 1 warrant for 0.40 common shares. Warrant holders chose to exchange 1,007,813 warrants with a fair value of approximately $75,000 for 403,125 shares of common stock with a fair value of approximately $73,000. On the date of the exchange, the Series B Warrants were first adjusted to fair value with the change in fair value being recorded in earnings. Redemption Put Liability As described in Note 14, the redemption put provision embedded in the Series D financing required bifurcation and measurement at fair value as a derivative. If the redemption put provision is triggered, it allows either payment in cash or the issuance of “Trigger Event Warrants”. Accordingly, the fair value of the Redemption put liability considered management’s estimate of the probability of cash payment versus payment in Trigger Event Warrants and was valued using a Monte Carlo Simulation which uses randomly generated stock-price paths obtained through a Geometric Brownian Motion stock price simulation. The fair value of the redemption provision was significantly influenced by the fair value of the Company’s stock price, stock price volatility, changes in interest rates and management’s assumptions related to the redemption factor. On July 28, 2020, the Series D Preferred Stock was converted into Common Stock, at which time the redemption put was no longer applicable and the fair value of the redemption put was adjusted to $0. The fair market value of the redemption put liability at inception was approximately $614,000 which was recorded as a liability and remeasured to fair value at the end of each reporting period. The change in fair value of approximately $273,000 and $347,000 was recorded as a component of other income (expense) in the Company’s consolidated statement of operations for the year ended December 31, 2020 and 2019, respectively. The fair value of the redemption put liability included on the consolidated balance sheet was approximately $0 and $267,000 as of December 31, 2020 and 2019, respectively.

Common Stock Warrants

Common Stock Warrants	12 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Common Stock Warrants	Note 13 - Common Stock Warrants A summary of the Company’s warrant issuance activity and related information for the years ended December 31, 2020 and December 31, 2019: Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life Assumed as of the January 8, 2019 merger 12,108,743 $ 1.38 1.53 Exchanged (1,007,813 ) 0.40 — Expired (2,183,478 ) 2.73 — Issued 35,888,624 $ 0.73 5.36 Outstanding and exercisable at December 31, 2019 44,806,076 $ 0.78 4.59 Issued 369,617,896 0.01 10.05 Exercised (1,000,000 ) 0.01 — Total outstanding and exercisable at December 31, 2020 413,423,972 0.015 10.30 The fair value of all warrants issued are determined by using the Lattice and Black-Scholes valuation techniques (see Note 12) and were assigned based on the relative fair value of both the common stock and the warrants issued. The inputs used in the Lattice and Black-Scholes valuation techniques (see Note 12) to value each of the warrants as of their respective issue dates are as follows: Event Description Date Number of Warrants H-CYTE Stock Price Exercise Price of Warrant Grant Date Fair Value Life of Warrant Risk Free Rate of Return (%) Annualized Volatility Rate (%) Private placement 1/8/2019 5,000,000 $ 0.40 $ 0.75 $ 0.24 3 years 2.57 115.08 Antidilution provision (1) 1/8/2019 2,023,438 $ 0.40 $ 0.40 $ 0.28 3 years 2.57 115.08 Private placement 1/18/2019 6,000,000 $ 0.40 $ 0.75 $ 0.23 3 years 2.60 114.07 Private placement 1/25/2019 1,250,000 $ 0.59 $ 0.75 $ 0.38 3 years 2.43 113.72 Private placement 1/31/2019 437,500 $ 0.54 $ 0.75 $ 0.34 3 years 2.43 113.47 Private placement 2/7/2019 750,000 $ 0.57 $ 0.75 $ 0.36 3 years 2.46 113.23 Private placement 2/22/2019 375,000 $ 0.49 $ 0.75 $ 0.30 3 years 2.46 113.34 Private placement 3/1/2019 125,000 $ 0.52 $ 0.75 $ 0.33 3 years 2.54 113.42 Private placement 3/8/2019 150,000 $ 0.59 $ 0.75 $ 0.38 3 years 2.43 113.53 Private placement 3/11/2019 2,475,000 $ 0.61 $ 0.75 $ 0.40 3 years 2.45 113.62 Private placement 3/26/2019 500,000 $ 0.51 $ 0.75 $ 0.32 3 years 2.18 113.12 Private placement 3/28/2019 375,000 $ 0.51 $ 0.75 $ 0.31 3 years 2.18 112.79 Private placement 3/29/2019 62,500 $ 0.51 $ 0.75 $ 0.31 3 years 2.21 112.79 Private placement 4/4/2019 500,000 $ 0.48 $ 0.75 $ 0.29 3 years 2.29 112.77 Private placement 7/15/2019 200,000 $ 0.53 $ 1.00 $ 0.31 3 years 1.80 115.50 Convertible debt extension 9/18/2019 424,000 $ 0.40 $ 0.75 $ 0.25 3 years 1.72 122.04 Private placement of Series D Convertible Preferred Stock 11/15/2019 14,669,757 $ 0.28 $ 0.75 $ 0.19 10 years 1.84 89.75 Short-term note related party 11/26/2019 400,000 $ 0.20 $ 0.75 $ 0.13 3 years 1.58 144.36 Short-term note, related party 12/30/2019 171,429 $ 0.14 $ 0.75 $ 0.08 3 years 1.59 145.29 Short-term note, related party 1/13/2020 268,571 $ 0.12 $ 0.75 $ 0.07 3 years 1.60 145.76 Private placement of Series D Convertible Preferred Stock 1/17/2020 244,996 $ 0.15 $ 0.75 $ 0.13 10 years 1.84 144.30 Granted for bridge financing 4/8/2020 296,875 $ 0.05 $ 0.40 $ 0.02 3 years 0.34 131.82 Short-term note, related party conversion 4/17/2020 4,368,278 $ 0.05 $ 0.014 $ 0.05 10 years 0.65 100.64 Granted for bridge financing (2) 9/11/2020 364,439,176 $ 0.05 $ 0.014 $ 0.017 10 years 0.65 96.97 (1) (2) The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

Mezzanine Equity and Series D C

Mezzanine Equity and Series D Convertible Preferred Stock	12 Months Ended
	Dec. 31, 2020
Temporary Equity Disclosure [Abstract]
Mezzanine Equity and Series D Convertible Preferred Stock	Note 14- Mezzanine Equity and Series D Convertible Preferred Stock Series D Convertible preferred Stock On November 15, 2019, the Company entered into a securities purchase agreement with selected accredited investors whereby the Company offered (i) up to 238,871 shares of Series D Convertible Preferred Stock the (“Series D Shares”) at a price of $40.817 per share and (ii) a ten-year warrant (the “Series D Warrant”) to purchase 14,669,757 shares of common stock. The Series D Warrants are exercisable for a period of 10 years from issuance at an initial exercise price of $0.75 per share, subject to adjustment for traditional equity restructurings and reorganizations. On November 21, 2019, the Company entered into a securities purchase agreement with FWHC HOLDINGS, LLC an accredited investor for the purchase of 146,998 shares of Series D Preferred Stock, par value $0.001 per share and the Series D Warrant resulting in $6.0 million in gross proceeds to the Company (the “FWHC Investment”). The Company determined that the nature of the Series D Shares was more analogous to an equity instrument, and that the economic characteristics and risks of the embedded conversion option was clearly and closely related to the Series D Shares. As such, the conversion option was not required to be bifurcated from the host under ASC 815, Derivatives and Hedging The Company determined that the economic characteristics and risks of the embedded redemption provision were not clearly and closely related to the Series D Shares. The Company assessed the embedded redemption provision further, and determined it met the definition of a derivative and required classification as a derivative liability at fair value. On July 28, 2020, the Series D Shares were converted into shares of the Company’s common stock, at which time the redemption put liability was no longer applicable and its fair value was adjusted to $0. The Company’s approach to the allocation of the proceeds to the financial instruments was to first allocate basis to the redemption put liability at its fair values and the residual value to the Series D Shares and the Series D Warrants. Based upon the amount allocated to the Series D Shares the Company was required to determine if a beneficial conversion feature (“BCF”) was present. A BCF represents the intrinsic value in the convertible instrument, adjusted for amounts allocated to other financial instruments issued in the financing. The effective conversion price is calculated as the amount allocated to the convertible instrument divided by the number of shares to which it is indexed. However, a BCF is limited to the basis initially allocated. After allocating a portion of the proceeds to the other instruments, the effective conversion price was $0.24 compared to the share price of $0.28, resulting in a BCF of $623,045 or $0.04 per share for the year ended December 31, 2019. Based upon the above accounting conclusions and the additional information provided below, the allocation of the proceeds arising from the Series D Preferred financing transaction is summarized in the table below: November 21, 2019 Series D Convertible Preferred and warrant financing: Proceeds Allocation Financing Cost Allocation Total Allocation Gross proceeds $ 6,000,000 $ — $ 6,000,000 Financing costs paid in cash — (111,983 ) (111,983 ) $ 6,000,000 $ (111,983 ) $ 5,888,017 Derivative Liability: Derivative Put Liability $ (614,095 ) $ — $ (614,095 ) Deferred Financing costs — 8,100 8,100 Redeemable preferred stock: Series D Convertible Preferred Stock (2,869,854 ) — (2,869,854 ) Financing costs (APIC) — 1,106 1,106 Financing costs (Retained Earnings) — 66,265 66,265 Beneficial Conversion Feature (623,045 ) — (623,045 ) Investor Warrants (equity classified): Proceeds allocation (1,893,006 ) — (1,893,006 ) Financing costs (APIC) — 36,512 36,512 $ (6,000,000 ) $ 111,983 $ (5,888,017 ) Since the Series D Convertible Preferred Stock is perpetual and convertible at any time, the resulting discount of $3,130,146 was accreted as a Preferred Stock dividend on the date of issuance to record the Series D Convertible Preferred Stock to its redemption value of $6,000,000. On January 17, 2020, the Company entered into a securities purchase agreement with an accredited investor for the purchase of 2,450 shares of Series D Convertible Preferred Stock, par value $0.001 per share and a Series D Warrant resulting in $100,000 in gross proceeds to the Company. The Series D Convertible Preferred Stock and Warrants had the same terms as the FWHC Investment. There was no BCF associated with this financing because the effective conversion price after allocating a portion of the proceeds to the other instruments was higher than the share price. January 17, 2020 Series D Convertible Preferred and warrant financing: Proceeds Allocation Gross proceeds $ 100,000 Financing costs paid in cash — $ 100,000 Derivative Liability: Derivative Put Liability $ (5,305 ) Redeemable preferred stock: Series D Convertible Preferred Stock (62,793 ) Investor Warrants (equity classified): Proceeds allocation (31,902 ) $ (100,000 ) Since the Series D Convertible Preferred Stock is perpetual and convertible at any time, the resulting discount of $37,207 was accreted as a Preferred Stock dividend on the date of issuance to record the Series D Convertible Preferred Stock to its redemption value of $100,000. For the year ended December 31, 2020, the Company recorded approximately $278,000 in deemed dividends on the Series D Convertible Preferred Stock in accordance with the 8% stated dividend resulting in a total balance of Series D Convertible Preferred stock of $6,401,762. All outstanding shares of Series D Convertible Preferred Stock were converted into 15,773,363 shares of Common Stock on July 28, 2020. The conversion was pursuant to a mandatory conversion triggered by the majority holder of the Series D Convertible Preferred Stock as set forth in the Certificate of Designations. Mezzanine Equity Rollforward (Series D Convertible Preferred Stock) Balance at January 8, 2019 $ - Issuance of Series D Convertible Preferred Stock 2,869,853 Inception deemed dividend 3,130,147 Deemed dividend (8%) 60,493 Balance at December 31, 2019 6,060,493 Issuance of Series D Convertible Preferred Stock 62,793 Inception deemed dividend 37,207 Deemed dividend (8%) 277,719 Mandatory conversion of Series D Convertible Preferred Stock to Common Stock (6,438,212 ) Balance at December 31, 2020 $ - Series D Convertible Preferred Stock Preferences Voting Rights Holders of our Series D Convertible Preferred Stock (“Series D Holders”) have the right to receive notice of any meeting of holders of common stock or Series D Convertible Preferred Stock and to vote upon any matter submitted to a vote of the holders of common stock or Series D Convertible Preferred Stock. Each Series D Holder shall vote on each matter submitted to them with the holders of common stock. There are no shares of Series D Convertible Preferred Stock outstanding as of December 31, 2020. Liquidation Upon the liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, each Series D Holder shall be entitled to receive, for each share thereof, out of assets of the Company legally available therefore, a preferential amount in cash equal to the stated value plus all accrued and unpaid dividends. All preferential amounts to be paid to the Series D Holders in connection with such liquidation, dissolution or winding up shall be paid before the payment or setting apart for payment of any amount for, or the distribution of any assets of the Company’s to the holders of the Company’s Series B and common stock. The Company accrues these dividends as they are earned each period.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Note 15 - Income Taxes The Company utilizes the liability method of accounting for income taxes as set forth in FASB ASC Topic 740, “Income Taxes”. Under the liability method, deferred taxes are determined based on differences between the financial statement and tax bases of assets and liabilities using tax rates expected to be in effect during the years in which the basis difference reverses. The Company accounts for interest and penalties on income taxes as income tax expense. A valuation allowances is recorded when it is more likely than not that a tax benefit will not be realized. In determining the need for valuation allowances the Company considers projected future taxable income and the availability of tax planning strategies. The Company’s policy is to record interest and penalties on uncertain tax positions as a component of income tax expense. As of December 31, 2020, the Company has not recorded any uncertain tax positions and, therefore, has not incurred any interest or penalties. The Company is not currently under examination by any Federal or State authority and is no longer subject to federal or state examination for years prior to 2017. A reconciliation of the statutory federal income tax expense (benefit) to the effective tax is as follows for the years ended December 31: 2020 2019 Statutory rate – federal 21.0 % 21.0 % Effect of: State income tax, net of federal benefit 5.1 3.0 State NOL true-up (1.1 ) (2.0 ) Goodwill impairment - (9.0 ) Prior year true up 2.7 - Other permanent differences 3.0 (1.0 ) Change in valuation allowances (30.7 ) (13.0 ) Income taxes 0.0 % 0.0 % The Company’s financial statements contain certain deferred tax assets which have arisen primarily as a result of losses incurred that are considered start-up costs for tax purposes, as well as net deferred income tax assets resulting from other temporary differences related to certain reserves and differences between book and tax depreciation and amortization. The Company assesses the realizability of deferred tax assets based on the available evidence, including a history of taxable income and estimates of future taxable income. In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that all or some portion of deferred tax assets will not be realized. Due to the history of losses incurred by the Company, management believes it is not more likely than not that all of the deferred tax assets can be realized. Accordingly, the Company established and recorded a full valuation allowance on its net deferred tax assets of $12.5 million and $10.5 million as of December 31, 2020 and 2019, respectively. Deferred tax assets and liabilities consist of the following at December 31: 2020 2019 Deferred Tax Assets: Federal and state net operating loss carry forwards $ 9,512,596 $ 7,302,375 Capitalized start-up costs 2,210,392 2,483,736 Capitalized research and development costs 462,768 424,390 Patents 41,842 57,907 Share-based compensation 241,177 242,437 Other 112,376 25,405 Total gross deferred tax assets 12,581,151 10,536,250 Deferred Tax Liabilities Right-of-use asset (70,914 ) — Total gross deferred tax liabilities (70,914 ) — Valuation Allowance (12,510,237 ) (10,536,250 ) Net deferred tax assets $ — — Utilization of the net operating loss carryforwards is subject to a substantial annual limitation due to the “ownership change” limitations provided by Section 382 and 383 of the Internal Revenue Code of 1986, as amended, and other similar state provisions. Any annual limitation may result in the expiration of net operating loss carryforwards before utilization. As of December 31, 2020, the Company had $39.7 million of U.S. federal net operating loss carryforwards available to reduce future taxable income, of which $32.5 million will be carried forward indefinitely for U.S. federal tax purposes and $7.2 million will expire beginning in 2035 to 2037. The Company also has $26.0 million of U.S. state net operating loss carryforwards of which $25.3 million will be carried forward indefinitely and $.7 million that will expire beginning in 2035 to 2037.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	N ote 16 - Subsequent Events On January 12, 2021, Mr. William Horne stepped down as Chairman of the board of directors (the “Board”) of H-Cyte, Inc. (the “Company”). Mr. Horne will remain a member of the Board. On January 12, 2021, Mr. Raymond Monteleone was appointed the new Chairman of the Board. Mr. Monteleone is a current member of the Board. As of March 24, 2021, an additional 8,950,400 Series A Preferred Stock was converted into Common Stock as the request of certain Series A Preferred Stockholders.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation U.S. GAAP requires that a related entity be consolidated with a company when certain conditions exist. An entity is considered to be a VIE when it has equity investors who lack the characteristics of having a controlling financial interest, or its capital is insufficient to permit it to finance its activities without additional subordinated financial support. Consolidation of a VIE by the Parent would be required if it is determined that the Parent will absorb a majority of the VIE’s expected losses or residual returns if they occur, retain the power to direct or control the VIE’s activities, or both. The accompanying audited consolidated financial statements include the accounts of the Parent, its wholly owned subsidiaries, and its VIEs. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates In preparing the financial statements, U.S. GAAP requires disclosure regarding estimates and assumptions used by management that affect the amounts reported in financial statements and accompanying notes. Significant estimates were made around the valuation of embedded derivatives, which impacts gains or losses on such derivatives, the carrying value of debt, interest expense, and deemed dividends. Actual results could differ from those estimates.
Cash	Cash The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The Company’s cash balances at December 31, 2020 and 2019 consists of funds deposited in checking accounts with commercial banks.
Accounts Receivable	Accounts Receivable Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables. Trade accounts receivable are stated net of an estimate made for doubtful accounts, if any. Management evaluates the adequacy of the allowance for doubtful accounts regularly to determine if any account balances will potentially be uncollectible. Customer account balances are considered past due or delinquent based on the contractual agreement with each customer. Accounts are written off when, in management’s judgment, they are considered uncollectible. At December 31, 2020 and 2019, management believes no allowance is necessary. For the year ended December 31, 2020 and 2019, the Company recorded bad debt expense of approximately $6,000 and $90,000, respectively.
Impairment of Long-lived Assets	Impairment of Long-Lived Assets The Company reviews the values assigned to long-lived assets, including property and equipment and certain intangible assets, to determine whether events and circumstances have occurred which indicate that the remaining estimated useful lives may warrant revision or that the remaining balances may not be recoverable. The evaluation of asset impairment requires management to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment, and actual results may differ from estimated amounts. In such reviews, undiscounted cash flows associated with these assets are compared with their carrying value to determine if a write-down to fair value is required (see Note 7).
Goodwill	Goodwill Goodwill represents the excess of purchase price over fair value of net identified tangible and intangible assets and liabilities acquired. The Company does not amortize goodwill; it tests goodwill for impairment on at least an annual basis. An impairment loss, if any, is measured as the excess of the carrying value of the reporting unit over the fair value of the reporting unit (see Note 7).
Leases	Leases In February 2016, the Financial Accounting Standard Board (“FASB”) established Topic 842, Leases, by issuing Accounting Standards Update (ASU) No. 2016-02 (as amended), which requires lessees to recognize leases on the balance sheet and disclose key information about leasing arrangements. The new standard establishes a right-of-use (“ROU”) model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than twelve months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. The Company has not entered into significant lease agreements in which it is the lessor. For the lease agreements in which the Company is the lessee, under Topic 842, lessees are required to recognize a lease liability and right-of-use asset for all leases (except for short-term leases) at the lease commencement date. Effective January 1, 2019, the Company adopted this guidance, applied the modified retrospective transition method and elected the transition option to use the effective date as the date of initial application. The Company recognized the cumulative effect of the transition adjustment on the consolidated balance sheet as of the effective date and did not provide any new lease disclosures for periods before the effective date. With respect to the practical expedients, the Company elected the package of transitional-related practical expedients and the practical expedient not to separate lease and non-lease components.
Other Receivables	Other Receivables Other receivables totaling approximately $22,000 and $19,000 at December 31, 2020 and 2019, respectively include receivables from the non-acquired Lung Institute, LLC due to Lung Institute Tampa, LLC for approximately $3,000 and $10,000. Other receivables totaling approximately $19,000 and $9,000 include reimbursement receivables for expenses from RMS at December 31, 2020 and 2019, respectively.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with U.S. GAAP as outlined in the FASB ASC 606, Revenue From Contracts with Customers The Company uses a standard pricing model for the types of cellular therapy treatments that is offered to its patients. The transaction price accounts for medical, surgical, facility, and office services rendered by the Company for consented procedures and is recorded as revenue. The Company recognizes revenue when the terms of a contract with a patient are satisfied. The Company offers two types of cellular therapy treatments to their patients. 1) The first type of treatment includes medical services rendered typically over a two-day period in which the patient receives cellular therapy. For this treatment type, revenue is recognized in full at time of service. 2) The Company also offers a four-day treatment in which medical services are rendered typically over a two-day period and then again, approximately three months later, medical services are rendered for an additional two days of treatment. Payment is collected in full for both service periods at the time the first treatment is rendered. Revenue is recognized when services are performed based on the estimated standalone selling price of each service. The Company has deferred recognition of revenue amounting to approximately $634,000 and $1,046,000 at December 31, 2020 and 2019, respectively. The Company’s policy is to not offer refunds to patients. However, in limited instances the Company may make exceptions to this policy for extenuating circumstances. These instances are evaluated on a case-by-case basis and may result in a patient refund. Management performed an analysis of its customer refund history for refunds issued related to prior year’s revenue. Management used the results of this historical refund analysis to record a reserve for anticipated future refunds related to recognized revenue. At December 31, 2020 and 2019, the estimated allowance for refunds was approximately $77,000 and $63,000, respectively and is recorded in a contra revenue account.
Research and Development Costs	Research and development costs Research and development expenses are recorded in operating expenses in the period in which they are incurred.
Advertising	Advertising Advertising costs are recorded in operating expenses in the period in which they are incurred.
Stock-based Compensation	Stock-Based Compensation The Company maintains a stock option incentive plan and accounts for stock-based compensation in accordance with ASC 718, Compensation - Stock Compensation
Net Loss Per Share	Net Loss Per Share Basic loss per share is computed on the basis of the weighted average number of shares outstanding for the reporting period. Diluted loss per share is computed on the basis of the weighted average number of common shares plus potentially dilutive common shares outstanding using the treasury stock method. Any potentially dilutive securities are antidilutive due to the Company’s net losses.
Fair Value Measurements	Fair Value Measurements The Company measures certain non-financial assets, liabilities, and equity issuances at fair value on a non-recurring basis. These non-recurring valuations include evaluating assets such as long-lived assets and non-amortizing intangible assets for impairment; allocating value to assets in an acquired asset group; and applying accounting for business combinations. The Company classifies its stock warrants as either liability or equity instruments in accordance with ASC 480, “Distinguishing Liabilities from Equity” (ASC 480) and ASC 815, “Derivatives and Hedging” (ASC 815), depending on the specific terms of the warrant agreement. The Company uses the fair value measurement framework to value these assets and report the fair values in the periods in which they are recorded, adjusted above, or written down. The fair value measurement framework includes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair values in their broad levels. These levels from highest to lowest priority are as follows: ● Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities; ● Level 2: Quoted prices in active markets for similar assets or liabilities or observable prices that are based on inputs not quoted on active markets, but corroborated by market data; and ● Level 3: Unobservable inputs or valuation techniques that are used when little or no market data is available. The determination of fair value and the assessment of a measurement’s placement within the hierarchy requires judgment. Level 3 valuations often involve a higher degree of judgment and complexity. Level 3 valuations may require the use of various cost, market, or income valuation methodologies applied to unobservable management estimates and assumptions. Management’s assumptions could vary depending on the asset or liability valued and the valuation method used. Such assumptions could include estimates of prices, earnings, costs, actions of market participants, market factors, or the weighting of various valuation methods. The Company may also engage external advisors to assist us in determining fair value, as appropriate. The Company evaluates its financial liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments to be made. Although the Company believes that the recorded fair value of our financial instruments is appropriate at December 31, 2020, these fair values may not be indicative of net realizable value or reflective of future fair values.

Business Acquisition (Tables)

Business Acquisition (Tables)	12 Months Ended
	Dec. 31, 2020
Business Combinations [Abstract]
Schedule of Fair Value of Consideration Transferred	The acquisition-date fair value of the consideration transferred is as follows: Common shares issued and outstanding 24,717,270 Common shares reserved for issuance upon conversion of the outstanding Series B Preferred Stock 2,312,500 Total Common shares 27,029,770 Closing price per share of MedoveX Common stock on January 8, 2019 $ 0.40 10,811,908 Fair value of outstanding warrants and options 2,220,000 Cash consideration to RMS (350,000 ) Total consideration $ 12,681,908
Schedule of Estimated Fair Values of Assets Acquired and Liabilities Assumed	The following table summarizes the fair values of the assets acquired and liabilities assumed at the date of acquisition on January 8, 2019: Cash $ (302,710 ) Accounts receivable 145,757 Inventory 131,455 Prepaid expenses 46,153 Property and equipment 30,393 Other 2,751 Intangibles 3,680,000 Goodwill 12,564,401 Total assets acquired $ 16,298,200 Accounts payable and other accrued liabilities 1,645,399 Derivative liability 1,215,677 Interest-bearing liabilities and other 755,216 Net assets acquired $ 12,681,908
Schedule of Interest Bearing and Other Liabilities Assumed	Total interest-bearing liabilities and other liabilities assumed are as follows: Notes payable $ 99,017 Short-term convertible notes payable 598,119 Dividend payable 57,813 Deferred rent 267 Total interest-bearing and other liabilities $ 755,216
Schedule of Revenue and Net Loss Attributable to Acquisition	The following schedule represents the amount of revenue and net loss attributable to the MedoveX acquisition which have been included in the consolidated statements of operations for the periods subsequent to the acquisition date: For the Year Ended December 31, 2019 Revenues $ 67,631 Net loss attributable to MedoveX $ (4,754,680 )

Right-of-use Asset and Lease _2

Right-of-use Asset and Lease Liability (Tables)	12 Months Ended
	Dec. 31, 2020
Leases [Abstract]
Schedule of Components of Lease Expense	The components of lease expense, included in other general and administrative expense, for the years ended December 31, 2020 and 2019, respectively, are as follows: December 31, 2020 December 31, 2019 Operating lease expense $ 548,622 $ 579,770
Schedule of Cash Paid for Amounts Included the Measurement of Lease Liabilities	Cash paid for amounts included in the measurement of lease liabilities for the years ended December 31, 2020 and 2019, respectively, are as follows: December 31, 2020 December 31, 2019 Operating cash flows from operating leases $ 548,622 $ 579,770
Schedule of Supplemental Balance Sheet and Other Information	Supplemental balance sheet and other information related to operating leases are as follows: December 31, 2020 December 31, 2019 Operating leases: Operating leases right-of-use assets $ 278,552 $ 738,453 Lease liability, current 139,189 453,734 Lease liability, net of current portion 157,050 302,175 Total operating lease liabilities $ 296,239 755,909 Weighted average remaining lease term 2.32 years 2.2 years Weighted average discount rate 10.31 % 7.75 %
Schedule of Maturities of Lease Liabilities	Maturities of operating lease liabilities as of December 31, 2020 are as follows: December 31, 2020 Due in one year or less $ 154,559 Due after one year through two years 102,891 Due after two years through three years 69,333 Total lease payments 326,783 Less interest (30,544 ) Total $ 296,239

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment, net, consists of the following: Useful Life December 31, 2020 December 31, 2019 Furniture and fixtures 5-7 years $ 231,222 $ 231,222 Computers and software 3-7 years 246,323 244,039 Leasehold improvements 15 years 155,583 157,107 633,128 632,368 Less accumulated depreciation (493,953 ) (412,665 ) Total $ 139,175 $ 219,703

Equity Transactions (Tables)

Equity Transactions (Tables)	12 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Summary of Stock Option Activity	The following is a summary of stock option activity for the years ending December 31, 2019 and December 31, 2020: Shares Weighted Average Exercise Price Weighted Average Remaining Term (Years) Outstanding at December 31, 2018 — — — Assumed with the RMS merger transaction 557,282 $ 2.78 6.06 Granted 250,000 0.40 9.02 Expired/Cancelled (382,282 ) 2.86 — Outstanding at December 31, 2019 425,000 $ 1.38 7.71 Granted — — — Expired/Cancelled (15,000 ) 1.35 — Outstanding and exercisable at December 31, 2020 410,000 $ 1.39 6.72

Derivative Liability - Warran_2

Derivative Liability - Warrants and Redemption Put (Tables)	12 Months Ended
	Dec. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Fair Value, Liabilities Measured On Recurring Basis	The following is a reconciliation of the beginning and ending balances for the liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the year ended December 31, 2020: Derivative Liability - Warrants Beginning balance as of December 31, 2018 $ — January 8, 2019 – date of dilutive financing 1,215,678 Exchange for common stock (72,563 ) Fair value adjustments (827,260 ) Balance at December 31, 2019 315,855 Series D Warrant reclass from equity to liability classification 509,764 Warrants issued with modification of Horne Management Notes 198,994 Warrants issued with April 17, 2020 financing 6,148,816 Fair value adjustments (2,986,853 ) Warrant reclassification from liability to equity classification (4,186,576 ) Balance at December 31, 2020 $ — Redemption Put Liability Beginning balance as of December 31, 2018 $ — November 15, 2019 – date of issuance 614,095 Fair value adjustments (346,696 ) Balance at December 31, 2019 $ 267,399 Issuance of Series D Convertible Preferred Stock 5,305 Fair value adjustments (272,704 ) Balance at December 31, 2020 $ —

Common Stock Warrants (Tables)

Common Stock Warrants (Tables)	12 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Summary of Warrant Activity	A summary of the Company’s warrant issuance activity and related information for the years ended December 31, 2020 and December 31, 2019: Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life Assumed as of the January 8, 2019 merger 12,108,743 $ 1.38 1.53 Exchanged (1,007,813 ) 0.40 — Expired (2,183,478 ) 2.73 — Issued 35,888,624 $ 0.73 5.36 Outstanding and exercisable at December 31, 2019 44,806,076 $ 0.78 4.59 Issued 369,617,896 0.01 10.05 Exercised (1,000,000 ) 0.01 — Total outstanding and exercisable at December 31, 2020 413,423,972 0.015 10.30
Schedule of Assumptions for Warrants	The fair value of all warrants issued are determined by using the Lattice and Black-Scholes valuation techniques (see note 12) and were assigned based on the relative fair value of both the common stock and the warrants issued. The inputs used in the Lattice and Black-Scholes valuation techniques (see note 12) to value each of the warrants as of their respective issue dates are as follows: Event Description Date Number of Warrants H-CYTE Stock Price Exercise Price of Warrant Grant Date Fair Value Life of Warrant Risk Free Rate of Return (%) Annualized Volatility Rate (%) Private placement 1/8/2019 5,000,000 $ 0.40 $ 0.75 $ 0.24 3 years 2.57 115.08 Antidilution provision (1) 1/8/2019 2,023,438 $ 0.40 $ 0.40 $ 0.28 3 years 2.57 115.08 Private placement 1/18/2019 6,000,000 $ 0.40 $ 0.75 $ 0.23 3 years 2.60 114.07 Private placement 1/25/2019 1,250,000 $ 0.59 $ 0.75 $ 0.38 3 years 2.43 113.72 Private placement 1/31/2019 437,500 $ 0.54 $ 0.75 $ 0.34 3 years 2.43 113.47 Private placement 2/7/2019 750,000 $ 0.57 $ 0.75 $ 0.36 3 years 2.46 113.23 Private placement 2/22/2019 375,000 $ 0.49 $ 0.75 $ 0.30 3 years 2.46 113.34 Private placement 3/1/2019 125,000 $ 0.52 $ 0.75 $ 0.33 3 years 2.54 113.42 Private placement 3/8/2019 150,000 $ 0.59 $ 0.75 $ 0.38 3 years 2.43 113.53 Private placement 3/11/2019 2,475,000 $ 0.61 $ 0.75 $ 0.40 3 years 2.45 113.62 Private placement 3/26/2019 500,000 $ 0.51 $ 0.75 $ 0.32 3 years 2.18 113.12 Private placement 3/28/2019 375,000 $ 0.51 $ 0.75 $ 0.31 3 years 2.18 112.79 Private placement 3/29/2019 62,500 $ 0.51 $ 0.75 $ 0.31 3 years 2.21 112.79 Private placement 4/4/2019 500,000 $ 0.48 $ 0.75 $ 0.29 3 years 2.29 112.77 Private placement 7/15/2019 200,000 $ 0.53 $ 1.00 $ 0.31 3 years 1.80 115.50 Convertible debt extension 9/18/2019 424,000 $ 0.40 $ 0.75 $ 0.25 3 years 1.72 122.04 Private placement of Series D Convertible Preferred Stock 11/15/2019 14,669,757 $ 0.28 $ 0.75 $ 0.19 10 years 1.84 89.75 Short-term note related party 11/26/2019 400,000 $ 0.20 $ 0.75 $ 0.13 3 years 1.58 144.36 Short-term note, related party 12/30/2019 171,429 $ 0.14 $ 0.75 $ 0.08 3 years 1.59 145.29 Short-term note, related party 1/13/2020 268,571 $ 0.12 $ 0.75 $ 0.07 3 years 1.60 145.76 Private placement of Series D Convertible Preferred Stock 1/17/2020 244,996 $ 0.15 $ 0.75 $ 0.13 10 years 1.84 144.30 Granted for bridge financing 4/8/2020 296,875 $ 0.05 $ 0.40 $ 0.02 3 years 0.34 131.82 Short-term note, related party conversion 4/17/2020 4,368,278 $ 0.05 $ 0.014 $ 0.05 10 years 0.65 100.64 Granted for bridge financing (2) 9/11/2020 364,439,176 $ 0.05 $ 0.014 $ 0.017 10 years 0.65 96.97 (1) (2)

Mezzanine Equity and Series D_2

Mezzanine Equity and Series D Convertible Preferred Stock (Tables)	12 Months Ended
	Dec. 31, 2020
Temporary Equity Disclosure [Abstract]
Schedule of Series D Convertible Preferred and Warrant Financing	Based upon the above accounting conclusions and the additional information provided below, the allocation of the proceeds arising from the Series D Preferred financing transaction is summarized in the table below: November 21, 2019 Series D Convertible Preferred and warrant financing: Proceeds Allocation Financing Cost Allocation Total Allocation Gross proceeds $ 6,000,000 $ — $ 6,000,000 Financing costs paid in cash — (111,983 ) (111,983 ) $ 6,000,000 $ (111,983 ) $ 5,888,017 Derivative Liability: Derivative Put Liability $ (614,095 ) $ — $ (614,095 ) Deferred Financing costs — 8,100 8,100 Redeemable preferred stock: Series D Convertible Preferred Stock (2,869,854 ) — (2,869,854 ) Financing costs (APIC) — 1,106 1,106 Financing costs (Retained Earnings) — 66,265 66,265 Beneficial Conversion Feature (623,045 ) — (623,045 ) Investor Warrants (equity classified): Proceeds allocation (1,893,006 ) — (1,893,006 ) Financing costs (APIC) — 36,512 36,512 $ (6,000,000 ) $ 111,983 $ (5,888,017 ) January 17, 2020 Series D Convertible Preferred and warrant financing: Proceeds Allocation Gross proceeds $ 100,000 Financing costs paid in cash — $ 100,000 Derivative Liability: Derivative Put Liability $ (5,305 ) Redeemable preferred stock: Series D Convertible Preferred Stock (62,793 ) Investor Warrants (equity classified): Proceeds allocation (31,902 ) $ (100,000 )
Schedule of Shares Outstanding	Mezzanine Equity Rollforward (Series D Convertible Preferred Stock) Balance at January 8, 2019 $ - Issuance of Series D Convertible Preferred Stock 2,869,853 Inception deemed dividend 3,130,147 Deemed dividend (8%) 60,493 Balance at December 31, 2019 6,060,493 Issuance of Series D Convertible Preferred Stock 62,793 Inception deemed dividend 37,207 Deemed dividend (8%) 277,719 Mandatory conversion of Series D Convertible Preferred Stock to Common Stock (6,438,212 ) Balance at December 31, 2020 $ -

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (benefit)	A reconciliation of the statutory federal income tax expense (benefit) to the effective tax is as follows for the years ended December 31: 2020 2019 Statutory rate – federal 21.0 % 21.0 % Effect of: State income tax, net of federal benefit 5.1 3.0 State NOL true-up (1.1 ) (2.0 ) Goodwill impairment - (9.0 ) Prior year true up 2.7 - Other permanent differences 3.0 (1.0 ) Change in valuation allowances (30.7 ) (13.0 ) Income taxes 0.0 % 0.0 %
Schedule of Deferred Tax Assets and Liabilities	Deferred tax assets and liabilities consist of the following at December 31: 2020 2019 Deferred Tax Assets: Federal and state net operating loss carry forwards $ 9,512,596 $ 7,302,375 Capitalized start-up costs 2,210,392 2,483,736 Capitalized research and development costs 462,768 424,390 Patents 41,842 57,907 Share-based compensation 241,177 242,437 Other 112,376 25,405 Total gross deferred tax assets 12,581,151 10,536,250 Deferred Tax Liabilities Right-of-use asset (70,914 ) — Total gross deferred tax liabilities (70,914 ) — Valuation Allowance (12,510,237 ) (10,536,250 ) Net deferred tax assets $ — —

Description of the Company (Det

Description of the Company (Details Narrative)	12 Months Ended
	Dec. 31, 2020	Sep. 11, 2020
FWHC, LLC [Member]
Equity ownership percentage		61.00%
Rion LLC [Member] | Product Supply Agreement [Member]
Agreement term	10 years

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Allowance for doubtful accounts
Bad debt expenses	6,000	$ 90,137
Other receivables	22,123	18,673
Deferred revenue recognition	634,149	1,046,156
Deferred revenue	634,000	1,046,000
Allowance for refunds	77,000	63,000
Uncertain tax positions
Lung Institute, LLC [Member]
Other receivables	3,000	10,000
Reimbursement receivable	$ 19,000	$ 9,000

Liquidity, Going Concern and _2

Liquidity, Going Concern and Management's Plans (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Mar. 24, 2021
Cash on hand	$ 1,640,645	$ 1,424,096
Net loss	(6,459,236)	(29,807,878)
Net cash used in operating activities	$ (7,257,743)	$ (12,291,275)
Subsequent Event [Member]
Cash on hand			$ 436,000

Business Acquisition (Details N

Business Acquisition (Details Narrative) - USD ($)	Feb. 06, 2019	Jan. 08, 2019	Feb. 28, 2019	Dec. 31, 2019	Sep. 30, 2018	Dec. 31, 2020	Dec. 31, 2019	Sep. 11, 2020
Shares issued during period, value							$ 4,419,787
Cash excluded from purchase		$ 302,710
Interest payable		755,216
Accounts payable		1,645,399
Market capitalization		10,811,908
Impairment charge				$ 2,944,000
Goodwill impairment charge				$ 12,564,000
Notes payable						$ 67,000
Common stock, par value				$ 0.001		$ 0.001	$ 0.001
Warrants to purchase common stock								363,146,765
Number of shares issued on conversion			250,000
Promissory Note [Member]
Debt maturity date						Mar. 1, 2021
Aggregate monthly installments amount						$ 5,800
Debt instrument interest rate				5.00%			5.00%
Notes payable		99,000		$ 78,000		67,000	$ 78,000
Accrued interest		$ 3,000
Debt outstanding balance				78,000			78,000
Promissory Note [Member] | COVID-19 [Member]
Accrued interest						$ 1,900
Convertible Notes [Member]
Notes payable				350,000			350,000
Debt conversion price per share	$ 0.36	$ 0.36
Number of shares issued on conversion	251,667					1,875,000
Series C Preferred Stock [Member]
Number of additional exchange shares issued		17,264
RMS [Member]
Common stock, par value						$ 33,700
RMS [Member] | Series C Preferred Stock [Member]
Number of shares issued for acquisition						33,661
Asset Purchase Agreement [Member]
Common stock, shares outstanding		24,500,000
Market capitalization		$ 9,800,000
Fair value of net assets		$ 8,400,000
Asset Purchase Agreement [Member] | RMS [Member]
Number of shares issued for acquisition		33,661
Number of additional shares issued		6,111
Number of shares issued for acquisition, value		$ 2,000,000
Number of shares converted		1,000
Percentage of voting interest acquired		55.00%
Shares issued during period, value		$ 5,650,000
Number of additional exchange shares issued		17,264
Cash excluded from purchase		$ 70,000
Convertible debt to a related party		4,300,000
Interest payable		158,000
Short-term notes, related party		180,000
Accounts payable		398,000
Other current liabilities		$ 285,000
Asset Purchase Agreement [Member] | RMS [Member] | Series C Preferred Stock [Member]
Number of shares issued for acquisition		39,772
Number of additional shares issued		11,153
Number of shares converted		17,263,889
Securities Purchase Agreement [Member]
Debt outstanding balance				$ 750,000			$ 750,000
Number of unites issued							15
Debt conversion price per share		$ 0.40		$ 0.40			$ 0.40
Proceeds from sale of convertible note and equity							$ 750,000
Warrants to purchase common stock				1,875,000			1,875,000
Number of shares issued on conversion							1,875,000
Proceeds from notes				$ 505,000
Proceeds from warrants				245,000
Fair value of notes payable				$ 598,000			$ 598,000
Securities Purchase Agreement [Member] | Convertible Notes [Member]
Debt instrument interest rate					12.00%
Number of unites issued					1,000,000
Purchase price per unit					$ 50,000
Debt conversion description					Each Unit consisted of (i) a 12% senior secured convertible note, initially convertible into shares of the Company's common stock, par value $0.001 per share, at a conversion price equal to the lesser of $0.40 or ninety percent (90%) of the per share purchase price of any shares of common stock or common stock equivalents issued in future private placements of equity and/or debt securities completed by the Company following this offering of Units, and (ii) a three-year warrant to purchase such number of shares of the Company's common stock equal to one hundred percent (100%) of the number of shares of common stock issuable upon conversion of the notes at $0.40. The warrants are exercisable at a price equal to the lesser of $0.75 or ninety percent (90%) of the per share purchase price of any shares of common stock or common stock equivalents issued in future private placements of the debt and/or equity securities completed by the Company following the issuance of warrants. As a result of the price adjustment feature, the conversion price of the convertible notes was adjusted to $0.36 per share.
Common stock, par value					$ 0.001
Debt conversion price per share					$ 0.40
Warrants term					3 years
Warrants exercise price, per share					$ 0.75
Conversion price description					As a result of the price adjustment feature, the conversion price of the convertible notes was adjusted to $0.36 per share.

Business Acquisition - Schedule

Business Acquisition - Schedule of Fair Value of Consideration Transferred (Details)	Jan. 08, 2019USD ($)$ / sharesshares
Business Combinations [Abstract]
Common shares issued and outstanding | shares	24,717,270
Common shares reserved for issuance upon conversion of the outstanding Series B Preferred Stock | shares	2,312,500
Total Common shares | shares	27,029,770
Closing price per share of MedoveX Common stock on January 8, 2019 | $ / shares	$ 0.40
Value of common shares	$ 10,811,908
Fair value of outstanding warrants and options	2,220,000
Cash consideration to RMS	(350,000)
Total consideration	$ 12,681,908

Business Acquisition - Schedu_2

Business Acquisition - Schedule of Estimated Fair Values of Assets Acquired and Liabilities Assumed (Details)	Jan. 08, 2019USD ($)
Business Combinations [Abstract]
Cash	$ (302,710)
Accounts receivable	145,757
Inventory	131,455
Prepaid expenses	46,153
Property and equipment	30,393
Other	2,751
Intangibles	3,680,000
Goodwill	12,564,401
Total assets acquired	16,298,200
Accounts payable and other accrued liabilities	1,645,399
Derivative liability	1,215,677
Interest-bearing liabilities and other	755,216
Net assets acquired	$ 12,681,908

Business Acquisition - Schedu_3

Business Acquisition - Schedule of Interest Bearing and Other Liabilities Assumed (Details)	Jan. 08, 2019USD ($)
Total interest-bearing and other liabilities	$ 755,216
Notes Payable [Member]
Total interest-bearing and other liabilities	99,017
Short-term Convertible Notes Payable [Member]
Total interest-bearing and other liabilities	598,119
Dividend Payable [Member]
Total interest-bearing and other liabilities	57,813
Deferred Rent [Member]
Total interest-bearing and other liabilities	$ 267

Business Acquisition - Schedu_4

Business Acquisition - Schedule of Revenue and Net Loss Attributable to Acquisition (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Revenues	$ 2,150,672	$ 8,346,858
Net loss attributable to MedoveX	$ (6,459,236)	(29,807,878)
Medovex Corp [Member]
Revenues		67,631
Net loss attributable to MedoveX		$ (4,754,680)

Right-of-use Asset and Lease _3

Right-of-use Asset and Lease Liability (Details Narrative) - USD ($)	Apr. 01, 2021	Nov. 02, 2020	Dec. 31, 2020	Dec. 31, 2019
Current lease liabilities			$ 139,189	$ 453,734
Long-term lease liabilities			157,050	302,175
ROU assets			278,552	738,453
Operating lease expense			$ 548,622	$ 579,770
Lease, description			Each location has its own expiration date ranging from April 30, 2020 to August 31, 2023. The Company did not renew the leases in Dallas, TX, Pittsburgh, PA, and Atlanta, GA as those leases all expired in 2020. The Company does not intend on renewing its corporate office space lease in Tampa, FL which expires on March 31, 2021 but will renew the Tampa, FL lease for the LHI clinic.
Nashville, TN [Member]
Short-term lease, cost		$ 73,750
Lease, description		Maturity date of October 31, 2021
Tampa, FL [Member] | Forecast [Member]
Short-term lease commitment, amount	$ 71,775
Lease, description	Maturity date of March 31, 2022.
Accounting Standards Update (ASU) No. 2016-02 [Member]
Current lease liabilities			$ 475,000
Long-term lease liabilities			713,000
ROU assets			$ 1,167,000

Right-of-use Asset and Lease _4

Right-of-use Asset and Lease Liability - Schedule of Components of Lease Expense (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Operating lease expense	$ 548,622	$ 579,770

Right-of-use Asset and Lease _5

Right-of-use Asset and Lease Liability - Schedule of Cash Paid for Amounts Included the Measurement of Lease Liabilities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Operating cash flows from operating leases	$ 548,622	$ 579,770

Right-of-use Asset and Lease _6

Right-of-use Asset and Lease Liability - Schedule of Supplemental Balance Sheet and Other Information (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Operating leases: Operating leases right-of-use assets	$ 278,552	$ 738,453
Operating leases: Lease liability, current	139,189	453,734
Operating leases: Lease liability, net of current portion	157,050	$ 302,175
Total operating lease liabilities	$ 296,239
Weighted average remaining lease term	2 years 3 months 26 days	2 years 2 months 12 days
Weighted average discount rate	10.31%	7.75%

Right-of-use Asset and Lease _7

Right-of-use Asset and Lease Liability - Schedule of Maturities of Lease Liabilities (Details)	Dec. 31, 2020USD ($)
Leases [Abstract]
Operating leases: Due in one year or less	$ 154,559
Operating leases: Due after one year through two years	102,891
Operating leases: Due after two years through three years	69,333
Operating leases: Total lease payments	326,783
Operating leases: Less interest	(30,544)
Total	$ 296,239

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 81,000	$ 98,000

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Property and equipment	$ 633,128	$ 632,368
Less: accumulated depreciation	(493,953)	(412,665)
Property and Equipment, net	139,175	219,703
Furniture and Fixtures [Member]
Property and equipment	$ 231,222	231,222
Furniture and Fixtures [Member] | Minimum [Member]
Useful Life	5 years
Furniture and Fixtures [Member] | Maximum [Member]
Useful Life	7 years
Computers and Software [Member]
Property and equipment	$ 246,323	244,039
Computers and Software [Member] | Minimum [Member]
Useful Life	3 years
Computers and Software [Member] | Maximum [Member]
Useful Life	7 years
Leasehold Improvements [Member]
Useful Life	15 years
Property and equipment	$ 155,583	$ 157,107

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Details Narrative)	3 Months Ended
	Dec. 31, 2019USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Accumulated amortization	$ 736,000
Non-cash charge of impair the carrying value oftechnology related intangible	2,944,000
Loss on impairment	$ 12,564,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)

Oct. 02, 2020

Sep. 11, 2020

Jul. 28, 2020

Jun. 02, 2020

Mar. 25, 2020

Nov. 13, 2019

Oct. 28, 2019

Sep. 26, 2019

Feb. 01, 2019

Apr. 30, 2020

Jan. 31, 2019

Dec. 31, 2020

Dec. 31, 2019

Dec. 31, 2018

Nov. 26, 2019

Jul. 25, 2019

Feb. 15, 2019

Warrants to purchase common stock

363,146,765

Gain on debt extinguishment

$ 1,300,088

Series A Preferred Stock [Member]

Conversion of stock, shares issued

117,362,143

Loan One [Member]

Loans payable

$ 900,000

Debt instrument interest rate

5.50%

Loan Two [Member]

Debt instrument interest rate

12.00%

Advance was repaid

$ 350,000

Debt, maturity date

Mar. 26, 2020

Increase in interest rate

15.00%

Loan Three [Member]

Debt instrument interest rate

12.00%

Advance was repaid

$ 150,000

Debt, maturity date

Apr. 28, 2020

Increase in interest rate

15.00%

Loan Four [Member]

Debt instrument interest rate

12.00%

Advance was repaid

$ 235,000

Debt, maturity date

May 13, 2020

Increase in interest rate

15.00%

Promissory Notes from April 2020 [Member] | Series A Preferred Stock [Member]

Conversion of stock, shares issued

123,031,819

April Secured Note [Member] | Series A Preferred Stock [Member]

Conversion of stock, shares issued

75,162,429

Hawes Notes [Member ] | Series A Preferred Stock [Member]

Conversion of stock, shares issued

35,860,079

Raymond Monteleone [Member]

Officers compensation

93,000

125,000

Michael Yurkowsky [Member]

Officers compensation

12,500

5,000

Bill Horne [Member]

Salary reduction per month

$ 0

Officers compensation

$ 12,500

Salary increase per month

$ 20,833

Deferred salary and compensation

$ 108,000

Lender [Member] | Loan Two [Member]

Warrants term

3 years

Warrants to purchase common stock

400,000

Warrants exercise price, per share

$ 0.75

Lender [Member] | Loan Three [Member]

Warrants term

3 years

Warrants to purchase common stock

171,429

Warrants exercise price, per share

$ 0.75

Lender [Member] | Loan Four [Member]

Warrants term

3 years

Warrants to purchase common stock

268,571

Warrants exercise price, per share

$ 0.75

Horne Management, LLC [Member] | Former CEO [Member] | Four Loans [Member]

Related party notes payable

1,635,000

FWHC HOLDINGS, LLC [Member]

Warrants term

10 years

Warrants exercise price, per share

$ 0.014

Percentage of fully diluted shares owned

61.00%

Warrants issued

273,356,676

FWHC HOLDINGS, LLC [Member] | Series D Convertible Preferred Stock [Member]

Conversion of stock, shares issued

15,518,111

Oral Consulting Agreement [Member]

Advisory service fee

$ 5,000

Audit fees

$ 2,500

Oral Consulting Agreement [Member] | Michael Yurkowsky [Member]

Officers compensation

$ 4,167

Oral Consulting Agreement [Member] | Mr.Raymond Monteleone [Member]

Advisory service fee

$ 10,000

Audit fees

$ 5,000

Oral Consulting Agreement [Member] | St. Louis Family Office, LLC [Member] | Jimmy St. Louis [Member]

Advisory service fee

$ 10,000

Audit fees

68,000

Consulting Agreement [Member] | Strategos Public Affairs, LLC [Member]

Audit fees

7,500

Compensation expenses

15,000

$ 71,000

Monthly fee

7,500

$ 4,500

April Offering [Member] | Bill Horne [Member]

Gain on debt extinguishment

$ 1,300,000

April Offering [Member] | Bill Horne [Member] | Warrants [Member]

Extinguished shares

4,368,278

April Offering [Member] | Bill Horne [Member] | Common Stock [Member]

Extinguished shares

4,368,278

Equity Transactions (Details Na

Equity Transactions (Details Narrative) - USD ($)	Sep. 24, 2020	Sep. 11, 2020	Jul. 29, 2020	Jul. 28, 2020	Jul. 28, 2020	Apr. 30, 2020	Apr. 23, 2020	Nov. 21, 2019	Apr. 25, 2019	Feb. 06, 2019	Jan. 08, 2019	Feb. 29, 2020	Aug. 31, 2019	Mar. 31, 2019	Feb. 28, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Mar. 31, 2020	Apr. 05, 2019
Common stock, par value																	$ 0.001	$ 0.001
Additional paid-in capital																	$ 42,515,999	$ 28,172,146
Accumulated deficit																	(43,858,974)	(37,362,531)
Non-controlling interest																	(370,132)	(370,132)
Share issued price per share														$ 0.40		$ 0.40
Shares issued during period, value																		4,419,787
Debt conversion of common stock shares															250,000
Number of shares issued for consulting fees														130,085
Number of shares issued for consulting fees, value														$ 52,033
Value of shares issued for services																	35,000	95,533
Warrants to purchase common stock		363,146,765
Authorized shares, description			The Company filed its Second Amended and Restated Certificate of Incorporation (the "Amended COI"). The Amended COI provides for the issuance of up 1,600,000,000 shares of Common Stock and 1,000,000,000 shares of Preferred Stock, of which 800,000,000 shares are designated as Series A Preferred Stock and eliminates the previously authorized classes of preferred stock. The Amended COI also delineates the rights of the Series A Preferred Stock.
Management fee																	0	0
LilyCon Investments, LLC [Member]
Share issued price per share												$ 0.32
Number of shares issued for services												109,375
Value of shares issued for services												$ 35,000
Home Management LLC [Member]
Debt instrument face amount							$ 1,717,000
Debt conversion of common stock shares							4,368,278
Debt conversion price per share							$ 0.014
Warrant term							10 years
Warrants exercise price, per share							$ 0.05
FWHC HOLDINGS, LLC [Member]
Warrant term		10 years
Warrants exercise price, per share		$ 0.014
Minimum [Member]
Shares issued during period, value											$ 5,650,000
Convertible Note [Member]
Debt instrument face amount																	750,000
Fair value of notes payable																	598,000
Promissory Note [Member]
Debt instrument face amount																		78,000
Promissory Notes from April 2020 [Member] | FWHC HOLDINGS, LLC [Member]
Number of shares converted	123,031,819
Hawes Notes [Member ] | FWHC HOLDINGS, LLC [Member]
Number of shares converted	35,860,079
Consultants [Member]
Share issued price per share													$ 0.29
Number of shares issued for services													150,000
Value of shares issued for services																		43,500
Warrant Holder [Member]
Warrants to purchase common stock		1,000,000
Former CEO [Member] | Restricted Stock Award [Member]
Compensation expense																	$ 1,000	95,000
Securities Purchase Agreement [Member]
Debt instrument face amount																		$ 750,000
Debt conversion of common stock shares																		1,875,000
Warrants to purchase common stock																		1,875,000
Debt conversion price per share											$ 0.40							$ 0.40
Number of common stock shares sold																		15
Fair value of notes payable																		$ 598,000
Securities Purchase Agreement [Member] | FWHC HOLDINGS, LLC [Member]
Stock issued during period new issue shares								146,998
Beneficial conversion feature																		$ 623,000
Securities Purchase Agreement [Member] | Convertible Note [Member]
Cancellation of debt										$ 100,000
Debt conversion of common stock shares										250,000
Debt conversion price per share										$ 0.40
Debt instrument converted value										$ 100,000
Securities Purchase Agreement [Member] | Four Purchasers [Member]
Debt instrument face amount											$ 2,000,000
Proceeds from debt											1,800,000
Cancellation of debt											200,000
Proceeds from offering											8,000,000
Securities Purchase Agreement [Member] | Four Purchasers [Member] | Convertible Note [Member]
Debt instrument face amount											$ 50,000
Share issued price per share											$ 0.75
Securities Purchase Agreement [Member] | Additional Purchasers [Member]
Aggregate amount of capital raised																				$ 7,000,000
Employment Agreement [Member] | Mr. William Horne [Member]
Share issued price per share									$ 0.40
Shares issued during period, value									$ 4,225,634
Vested percentage									100.00%
Compensation expense									$ 1,690,000
Number of options to purchase shares of common stock									4,475,634
Percentage for common stock outstanding									7.00%
Number of options to purchase shares of common stock |									4,475,634
Employment Agreement [Member] | Former CEO [Member] | Stock Option [Member]
Number of options to purchase shares of common stock																		250,000
Number of options to purchase shares of common stock |																		250,000
Common Stock [Member]
Number of shares converted											17,263,889
Shares issued during period, value																		$ 17,700
Number of shares issued for services																	109,375	280,085
Value of shares issued for services																	$ 109	$ 280
Stock issued during period new issue shares																		17,700,000
Potentially anti-dilutive, share																	410,000	425,000
Series B Warrant Holders [Member]
Share issued price per share																		$ 0.40
Shares issued during period, value																		$ 73,000
Warrants to purchase common stock																		1,007,813
Fair value of warrants																		$ 75,000
Stock issued during period new issue shares																		403,125
Series B and Series D Preferred Stock [Member]
Debt conversion of common stock shares				17,893,076
Warrants [Member]
Warrants to purchase common stock																	387,126,145
Warrants exercise price, per share																	$ 0.016	$ 0.016	$ 0.016
Potentially anti-dilutive, share																	23,937,765	44,806,076
Series A Preferred Stock [Member]
Number of shares issued for acquisition	15,235,381	218,285,024
Stock issuance costs		$ 320,000
Share issued price per share	$ 0.014
Shares issued during period, value		$ 3,055,985
Series A Preferred Stock [Member] | Purchasers [Member]
Number of shares issued for acquisition	203,049,643
Series C Preferred Stock [Member]
Number of additional exchange shares issued											17,264
Series B Convertible Preferred Stock [Member]
Number of shares converted																		715,279
Value of converted shares																		$ 2,650
Beneficial conversion feature																$ 33,000
Preferred stock, par value																	$ 0.001	$ 0.001
Preferred stock, shares outstanding																	0	6,100
Series B Convertible Preferred Stock [Member] | Accrued Dividends [Member]
Number of shares converted																		50,367
Series B Convertible Preferred Stock [Member] | Securities Purchase Agreement [Member]
Debt conversion price per share											$ 0.36
Series A Preferred Stock [Member]
Number of shares converted																	4,020,031
Share issued price per share	$ 0.014
Stock issued during period new issue shares	15,235,381
Common stock conversion ratio																	Common stock at a 1:1 ratio
Preferred stock, par value																	$ 0.001	$ 0.001
Preferred stock, shares outstanding																	538,109,409	0
Preferred stock conversion terms																	The Company issued 538,109,409 shares of Series A Preferred Stock which converts on a 1:1 ratio to common stock and would be considered dilutive upon conversion.
Series A Preferred Stock [Member] | Promissory Note [Member]
Stock issued during period new issue shares	323,844,416					323,844,416
Principal amount and accrued interest						$ 4,483,617
Series A Preferred Stock [Member] | Promissory Notes from April 2020 [Member] | FWHC HOLDINGS, LLC [Member]
Number of shares converted	123,031,819
Series A Preferred Stock [Member] | April Secured Notes [Member] | FWHC HOLDINGS, LLC [Member]
Number of shares converted	75,162,429
Series A Preferred Stock [Member] | Hawes Notes [Member ]
Number of shares converted	35,860,079
Series A Preferred Stock [Member] | Outstanding Promissory Notes [Member]
Stock issued during period new issue shares	323,844,416
Principal amount and accrued interest						$ 4,483,617
Series A Preferred Stock [Member] | Purchasers [Member]
Stock issued during period new issue shares	203,049,643
Proceeds from offering	$ 3,055,985
Series B Convertible Preferred Stock [Member]
Number of shares converted																		715,279
Number of common stock shares sold																		9,250
Preferred stock, par value																		$ 0.001
Series B Convertible Preferred Stock [Member] | Accrued Dividends [Member]
Number of shares converted																		2,650
Series B and Series D Convertible Preferred Stock [Member]
Number of shares converted					17,893,076
Series D Preferred Stock [Member]
Preferred stock, shares outstanding
Series B Preferred Stock [Member]
Preferred stock, shares outstanding
RMS [Member]
Common stock, par value																	$ 33,700
Additional paid-in capital																	$ 3,566,000
Accumulated deficit																	9,296,000
Non-controlling interest																	$ 370,000
RMS [Member] | Common Stock [Member]
Number of shares converted																	33,661,000
RMS [Member] | Series C Preferred Stock [Member]
Number of shares issued for acquisition																	33,661

Equity Transactions - Summary o

Equity Transactions - Summary of Stock Option Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Equity [Abstract]
Number of Shares Options Outstanding Beginning Balance	425,000
Number of Shares Options, Assumed with the RMS merger transaction		557,282
Number of Options Granted		250,000
Number of Options Expired/Cancelled	(15,000)	(382,282)
Number of Shares Options Outstanding Ending Balance	410,000	425,000
Number of Shares Options Outstanding and exercisable Ending Balance	410,000
Weighted Average Exercise Price Outstanding Beginning Balance	$ 1.38
Weighted Average Exercise Price, Assumed with the RMS merger transaction		2.78
Weighted Average Exercise Price Granted		0.40
Weighted Average Exercise Price Expired/ Cancelled	1.35	2.86
Weighted Average Exercise Price Outstanding and exercisable Ending Balance	$ 1.39	$ 1.38
Weighted Average Remaining Term (years) Outstanding, Beginning	7 years 8 months 16 days	0 years
Weighted Average Remaining Term (years) Assumed with the RMS merger transaction	0 years	6 years 22 days
Weighted Average Remaining Term (years) Granted	0 years	9 years 3 months 8 days
Weighted Average Remaining Term (years) Outstanding, Ending	0 years	7 years 8 months 16 days
Weighted Average Remaining Term (years) Outstanding and exercisable Ending	6 years 11 months 23 days

Commitments & Contingencies (De

Commitments & Contingencies (Details Narrative)	Jan. 02, 2021USD ($)	Jun. 15, 2020USD ($)	Mar. 31, 2020USD ($)	Feb. 29, 2020$ / sharesshares	Oct. 09, 2019USD ($)	Aug. 29, 2019$ / sharesshares	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2019EUR (€)	Mar. 31, 2019$ / shares
Stock per share | $ / shares										$ 0.40
Professional average fee		$ 20,000
Increase in professional average fee percentage		5.00%
Guarantor obligations							$ 36,000	$ 141,000
Research and development expense							1,152,065	106,214
Subsequent Event [Member]
Monthly fees	$ 22,500
LilyCon Investments, LLC [Member]
Stock per share | $ / shares				$ 0.32
Rion LLC [Member]
Research and development expense							1,150,000	0
Consulting Agreements [Member]
Stock issued during period new issue shares | shares						62,500
Stock per share | $ / shares						$ 0.29
Total incurred expense							10,000	83,000
Consulting Agreements [Member] | Jesse Crowne [Member]
Consulting fees								5,000
Consulting Agreement [Member] | LilyCon Investments, LLC [Member]
Consulting fees								12,500
Stock issued during period new issue shares | shares				35,000
Stock per share | $ / shares				$ 0.31
Signing bonus								$ 15,000
Agreement, description								The agreement also provides LilyCon Investments with $35,000 in stock (to be calculated using an annual variable weighted average price from February 2019 through January 2020) to be granted on the one-year anniversary of this agreement, if the agreement has not been terminated prior to that date.	The agreement also provides LilyCon Investments with $35,000 in stock (to be calculated using an annual variable weighted average price from February 2019 through January 2020) to be granted on the one-year anniversary of this agreement, if the agreement has not been terminated prior to that date.
Compensation expenses							65,000	$ 153,000
Total number of shares issued | shares				106,061
Monthly fees			$ 5,000
Agreement maturity date			Apr. 1, 2020
Consulting Agreement [Member] | Goldin Solutions [Member]
Total incurred expense							99,000	162,000
Monthly fees								$ 34,650
Agreement maturity date								Mar. 31, 2020	Mar. 31, 2020
Consulting Agreement [Member] | Goldin Solutions [Member] | Plus Expenses Payable Each Month [Member]
Monthly fees								$ 34,650
Consulting Agreement [Member] | Goldin Solutions [Member] | First Month Discount [Member]
Monthly fees								12,600
Distribution Center and Logistic Services Agreement [Member]
Total incurred expense							$ 56,000	49,000
Monthly fees								5,050
Distribution Center and Logistic Services Agreement [Member] | Minimum [Member]
Monthly fees								2,300
Distribution Center and Logistic Services Agreement [Member] | Maximum [Member]
Monthly fees								$ 8,300
Distribution Center and Logistic Services Agreement [Member] | EURO [Member]
Monthly fees | €									€ 4,500
Distribution Center and Logistic Services Agreement [Member] | EURO [Member] | Minimum [Member]
Monthly fees | €									1,900
Distribution Center and Logistic Services Agreement [Member] | EURO [Member] | Maximum [Member]
Monthly fees | €									€ 6,900
Rion Agreement [Member] | Rion LLC [Member]
Expenses incurred upon achievement of milestones					$ 350,000

Debt (Details Narrative)

Debt (Details Narrative) - USD ($)	Sep. 24, 2020	Sep. 11, 2020	Apr. 30, 2020	Apr. 29, 2020	Apr. 23, 2020	Nov. 21, 2019	Feb. 06, 2019	Feb. 28, 2019	Dec. 31, 2020	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Apr. 09, 2020	Mar. 27, 2020	Sep. 30, 2019	Mar. 31, 2019	Jan. 08, 2019	Sep. 30, 2018
Common stock, par value									$ 0.001		$ 0.001	$ 0.001	$ 0.001
Debt conversion of common stock shares								250,000
Notes payable									$ 67,000			$ 67,000
Interest expense												1,462,750	$ 299,331
Fair value of warrants												(2,986,854)	(827,260)
Gain on extinguishment of debt												$ 1,300,088
Share issued price per share																	$ 0.40
Warrants [Member]
Warrants exercise price, per share									$ 0.016	$ 0.016	$ 0.016	$ 0.016	$ 0.016
Number of warrants issued										840,000	840,000
Preferred Series B Stock [Member]
Stock issued during period new issue shares
Home Management LLC [Member]
Market value of common stock					$ 0.014
Warrant term					10 years
Warrants exercise price, per share					$ 0.05
Debt conversion of common stock shares					4,368,278
Debt principal amount					$ 1,717,000
Fair value of common stock					218,000
Fair value of warrants					199,000
Gain on extinguishment of debt					$ 1,300,000
FWHC HOLDINGS, LLC [Member]
Warrant term		10 years
Warrants exercise price, per share		$ 0.014
Consisting of Four Loans [Member] | Home Management LLC [Member] | March 31, 2020 and December 31, 2019 [Member]
Notes payable									$ 1,635,000			$ 1,635,000
Consisting of Four Loans [Member] | Home Management LLC [Member] | March 31, 2020 and December 31, 2019 [Member] | Minimum [Member]
Debt, maturity date												Mar. 26, 2020
Debt instrument interest rate									5.50%			5.50%
Consisting of Four Loans [Member] | Home Management LLC [Member] | March 31, 2020 and December 31, 2019 [Member] | Maximum [Member]
Debt, maturity date												May 13, 2020
Debt instrument interest rate									12.00%			12.00%
Series A Preferred Stock [Member]
Share issued price per share	$ 0.014
Stock issued during period new issue shares	15,235,381
Number of shares converted												4,020,031
William E. Horne [Member] | Home Management LLC [Member]
Debt interest rate description												The loans bore interest rates ranging from 5.5% to 12%, in some cases increasing to 15% if not paid by the respective maturity date ranging from March 26, 2020 to May 13, 2020.
Investor [Member]
Notes payable														$ 500,000	$ 500,000
Debt instrument interest rate														12.00%
Investor [Member] | Preferred Series B Stock [Member]
Share issued price per share														$ 0.014
Short-term Convertible Notes Payable [Member]
Debt description							Eliminating $100,000 of the Company's debt obligation.
Market value of common stock							$ 0.36											$ 0.36
Debt conversion of common stock shares							251,667					1,875,000
Deemed dividend												$ 288,000
Proceeds from debt							$ 100,000
Debt conversion convertible outstanding							$ 750,000
Notes payable											$ 350,000		$ 350,000
Short-term Convertible Notes Payable [Member] | Three of the Noteholders [Member]
Accrued interest											52,033		52,033
Third Noteholder [Member]
Conversion of common stock, percentage												10.00%
Notes payable									$ 300,000			$ 300,000
Accrued interest									40,000			$ 40,000
Debt, maturity date												Sep. 30, 2020
Fees and penalties									$ 85,000			$ 85,000
Debt principal amount											424,615		424,615			$ 424,615
Debt instrument interest rate									11.90%			11.90%
Interest expense									$ 10,000
Hawes Note [Member] | Series A Preferred Stock [Member]
Debt amount plus accrued interest		$ 35,860,079
Notes Payable [Member] | Merger [Member]
Debt description												The Company finalized an eighteen-month extension to March 1, 2021.
Accrued interest									$ 1,900			$ 1,900
Debt, maturity date												Aug. 1, 2019
Debt instrument interest rate									5.00%			5.00%
Monthly installment amount												$ 5,800
Promissory Notes [Member]
Notes payable									$ 67,000		78,000	67,000	78,000
New Principal Amount [Member] | Investor [Member]
Notes payable														$ 1,000,000
Promissory Note [Member]
Notes payable									$ 67,000		78,000	$ 67,000	78,000					$ 99,000
Accrued interest																		$ 3,000
Debt, maturity date												Mar. 1, 2021
Debt principal amount											$ 78,000		$ 78,000
Debt instrument interest rate											5.00%		5.00%
Debt amount plus accrued interest												$ 5,800
Promissory Note [Member] | Series A Preferred Stock [Member]
Stock issued during period new issue shares	323,844,416		323,844,416
Principal amount and accrued interest			$ 4,483,617
Promissory Notes from April 2020 [Member] | FWHC HOLDINGS, LLC [Member]
Number of shares converted	123,031,819
Promissory Notes from April 2020 [Member] | Series A Preferred Stock [Member] | FWHC HOLDINGS, LLC [Member]
Number of shares converted	123,031,819
April Secured Note [Member] | FWHC HOLDINGS, LLC [Member]
Number of shares converted	75,162,429
Hawes Notes [Member ] | FWHC HOLDINGS, LLC [Member]
Number of shares converted	35,860,079
Hawes Notes [Member ] | Series A Preferred Stock [Member]
Number of shares converted	35,860,079
Securities Purchase Agreement [Member]
Market value of common stock											$ 0.40		$ 0.40					$ 0.40
Debt conversion of common stock shares													1,875,000
Debt principal amount											$ 750,000		$ 750,000
Securities Purchase Agreement [Member] | FWHC HOLDINGS, LLC [Member]
Stock issued during period new issue shares						146,998
Securities Purchase Agreement [Member] | Short-term Convertible Notes Payable [Member]
Common stock, par value																			$ 0.001
Market value of common stock																			$ 0.40
Warrant term																			3 years
Warrants exercise price, per share																			$ 0.75
Debt instrument interest rate																			12.00%
Securities Purchase Agreement [Member] | Accredited Investors [Member]
Number of common stock shares sold, value												$ 750,000
Sale of stock price per share									$ 50,000			$ 50,000
Debt description												Each Unit consists of (i) a 12% senior secured convertible note, initially convertible into shares of the Company's common stock, par value $0.001 per share, at a conversion price equal to the lesser of $0.40 or ninety percent (90%) of the per share purchase price of any shares of common stock or common stock equivalents issued in future private placements of equity and/or debt securities completed by the Company following this offering, and (ii) a three-year warrant to purchase such number of shares of the Company's common stock equal to one hundred percent (100%) of the number of shares of common stock issuable upon conversion of the notes at $0.40. The Warrants were initially exercisable at a price equal to the lesser of $0.75 or ninety percent (90%) of the per share purchase price of any shares of common stock or common stock equivalents issued in future private placements of the debt and/or equity securities completed by the Company following the issuance of warrants.
Conversion of common stock, percentage												12.00%
Common stock, par value									0.001			$ 0.001
Market value of common stock									$ 0.40			$ 0.40
Warrant term									3 years			3 years
Warrants exercise price, per share									$ 0.75			$ 0.75
Payroll Protection Program [Member]
Debt principal amount				$ 809,082
Debt instrument interest rate				1.00%
Debt repayments, description				The PPP Loan bears interest at a rate of 1% per annum and is payable in eighteen monthly payments of $45,533 beginning on approximately August 14, 2021. The Company elected to use a 24-week Covered Period, per the SBA Paycheck Protection Program guidelines, the Covered Period ended on October 14, 2020.
Amount forgiven to non-payroll costs, percentage				40.00%

Derivative Liability - Warran_3

Derivative Liability - Warrants and Redemption Put (Details Narrative)	Sep. 11, 2020USD ($)$ / sharesshares	Jul. 28, 2020USD ($)	Apr. 23, 2020USD ($)$ / sharesshares	Jan. 08, 2019USD ($)$ / shares	May 31, 2018$ / sharesshares	Feb. 28, 2019shares	May 31, 2018shares	Dec. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)
Warrants to purchase common stock | shares	363,146,765
Warrant upper exercise price | $ / shares				$ 0.75
Warrant lower exercise price | $ / shares				$ 0.40
Additional warrant issued				$ 2,023,438
Fair value of the derivative liability								$ 0	$ 316,000
Fair value of warrants								(2,986,854)	(827,260)
Debt conversion of common stock shares | shares						250,000
Fair value of the redemption put								614,000
Redemption put liability		$ 0							267,399
Series D Preferred Stock [Member]
Fair value of the redemption put		$ 0
Other Income [Member]
Re-measured value change in fair value of derivative								2,987,000	827,000
Other Income [Member] | Redemption Put Liability [Member]
Re-measured value change in fair value of derivative								98,000
Other Expense [Member] | Redemption Put Liability [Member]
Re-measured value change in fair value of derivative								$ 273,000
Other Income Expense [Member] | Redemption Put Liability [Member]
Re-measured value change in fair value of derivative									347,000
Home Management LLC [Member]
Warrant term			10 years
Warrants exercise price | $ / shares			$ 0.05
Fair value of warrants			$ 199,000
Debt conversion of common stock shares | shares			4,368,278
Measurement Input, Exercise Price [Member] | Home Management LLC [Member]
Warrants measurement input			0.014
Measurement Input, Stock Price Volatility [Member]
Warrants measurement input								100.64
Measurement Input, Stock Price Volatility [Member] | Home Management LLC [Member]
Warrants measurement input			101
Measurement Input, Risk Free Interest Rate [Member]
Warrants measurement input								0.65
Measurement Input, Risk Free Interest Rate [Member] | Home Management LLC [Member]
Warrants measurement input			0.65
April 2020 Offering [Member]
Fair value of the derivative liability								$ 317,000
Series B Warrants [Member]
Warrants to purchase common stock | shares								403,125
Fair value of the derivative liability									$ 1,200,000
Warrant description								The Company offered the Series B warrant holders the option to exchange their warrants on the basis of 1 warrant for 0.40 common shares. Warrant holders chose to exchange 1,007,813 warrants with a fair value of approximately $75,000 for 403,125 shares of common stock with a fair value of approximately $73,000.
Warrants exercise price | $ / shares	$ 0.014
Fair value of warrants	$ 73,805							$ 73,000
Warrants | shares								1,007,813
Series B Warrants [Member] | Minimum [Member]
Warrant term	8 months 12 days
Series B Warrants [Member] | Maximum [Member]
Warrant term	1 year 3 months 29 days
Series B Warrants [Member] | Measurement Input, Trading Market [Member]
Warrants measurement input	0.027
Series B Warrants [Member] | Measurement Input, Exercise Price [Member]
Warrants measurement input	0.014
Series B Warrants [Member] | Measurement Input, Stock Price Volatility [Member] | Minimum [Member]
Warrants measurement input	222
Series B Warrants [Member] | Measurement Input, Stock Price Volatility [Member] | Maximum [Member]
Warrants measurement input	260
Series B Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Warrants measurement input	0.12
Series B Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Warrants measurement input	0.13
Series B Warrants [Member] | April 2020 Offering [Member]
Fair value of the derivative liability								$ 71,000
Warrant description								The Company issued an additional 296,875 warrants to a certain Series B holder as compensation to terminate their anti-dilution price protection. The Company also issued 1,292,411 warrants to a certain Series B holder who was non-responsive in the Company's request to terminate their anti-dilution price protection
Series D Warrants [Member]
Warrants to purchase common stock | shares								14,944,753
Warrant term	9 years 7 days
Warrants exercise price | $ / shares	$ 0.014							$ 0.75
Fair value of warrants	$ 337,400
Series D Warrants [Member] | Home Management LLC [Member]
Warrant term	10 years
Warrants exercise price | $ / shares	$ 0.014
Fair value of warrants	$ 107,123
Series D Warrants [Member] | Fair Value Before and After Modification [Member]
Fair value of the derivative liability								$ 510,000
Series D Warrants [Member] | Measurement Input, Trading Market [Member]
Warrants measurement input	0.027
Series D Warrants [Member] | Measurement Input, Trading Market [Member] | Home Management LLC [Member]
Warrants measurement input	0.027
Series D Warrants [Member] | Measurement Input, Exercise Price [Member]
Warrants measurement input	0.014
Series D Warrants [Member] | Measurement Input, Exercise Price [Member] | Home Management LLC [Member]
Warrants measurement input	0.014
Series D Warrants [Member] | Measurement Input, Stock Price Volatility [Member]
Warrants measurement input	111
Series D Warrants [Member] | Measurement Input, Stock Price Volatility [Member] | Home Management LLC [Member]
Warrants measurement input	103
Series D Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants measurement input	0.67
Series D Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | Home Management LLC [Member]
Warrants measurement input	0.67
April Bridge Loan and Converted Advance Warrants [Member] | April 2020 Offering [Member]
Warrant term	10 years							10 years
Warrant description								The April Offering entitled the investors to warrants with the right to purchase up to 100% of the aggregate number of shares of Common Stock into which the Purchaser's Note may ultimately be converted. The Company also received a $1,000,000 advance which was converted into the April Secured Note and April Secured Note Warrants in April 2020. The April Secured Note Warrants entitle the holder to purchase up to 200% of the aggregate number of shares of Common Stock into which the April Secured Note may ultimately be converted. The Company received an aggregate of $2,842,695 in gross proceeds through the April Offering and an advance of $1,000,000 from the April Secured Note.
Warrants exercise price | $ / shares	$ 0.014
Fair value of warrants	$ 3,668,247							$ 6,149,000
April Bridge Loan and Converted Advance Warrants [Member] | April 2020 Offering [Member] | Exercise of Purchaser Warrants [Member]
Fair value of warrants	$ 212,821,929							$ 3,279,000
Number of shares issuable upon exercise of warrants, shares | shares								203,050,000
April Bridge Loan and Converted Advance Warrants [Member] | April 2020 Offering [Member] | April Secured Note Warrants [Member]
Fair value of warrants								$ 2,869,000
Number of shares issuable upon exercise of warrants, shares | shares								142,857,000
Warrants | shares	363,146,786
April Bridge Loan and Converted Advance Warrants [Member] | April 2020 Offering [Member] | Converted Advance Warrants [Member]
Fair value of warrants	$ 150,324,857
April Bridge Loan and Converted Advance Warrants [Member] | April 2020 Offering [Member] | Measurement Input, Trading Market [Member]
Warrants measurement input	0.027							0.05
April Bridge Loan and Converted Advance Warrants [Member] | April 2020 Offering [Member] | Measurement Input, Exercise Price [Member]
Warrants measurement input	0.014							0.014
April Bridge Loan and Converted Advance Warrants [Member] | April 2020 Offering [Member] | Measurement Input, Stock Price Volatility [Member]
Warrants measurement input	107							103
April Bridge Loan and Converted Advance Warrants [Member] | April 2020 Offering [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants measurement input	0.67							0.65
Securities Purchase Agreement [Member]
Stock issued during period new issue shares | shares							108,250
Securities Purchase Agreement [Member] | Series B Warrants [Member]
Warrants to purchase common stock | shares					2,312,500		2,312,500
Warrant term					3 years		3 years
Warrant upper exercise price | $ / shares					$ 0.75

Derivative Liability - Warran_4

Derivative Liability - Warrants and Redemption Put - Schedule of Fair Value, Liabilities Measured On Recurring Basis (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Derivative Liability - Warrants [Member]
Beginning balance, Derivative Liability- Warrants	$ 315,855
Exchange for common stock		(72,563)
Series D Warrant reclass from equity to liability classification	509,764
Warrants issued with modification of Horne Note	198,994
Warrants issued with April 17, 2020 financing	6,148,816
Fair value adjustments	(2,986,853)	(827,260)
Warrant reclassification from liability equity classification	(4,186,576)
Ending balance, Derivative Liability- Warrants		315,855
Redemption Put Liability [Member]
Beginning balance, Redemption Put Liability	267,399
Issuance of Series D Convertible Preferred Stock	5,305
Fair value adjustments	(272,704)	(346,696)
Ending balance		$ 267,399

Common Stock Warrants - Summary

Common Stock Warrants - Summary of Warrant Activity (Details) - $ / shares	Apr. 17, 2020	Dec. 31, 2020	Dec. 31, 2019
Equity [Abstract]
Number of Shares, Warrants Outstanding Beginning		44,806,076	12,108,743
Number of Shares, Warrants Exchanged			(1,007,813)
Number of Shares, Warrants Expired			(2,183,478)
Number of Shares, Warrants Issued	354,836,286	369,617,896	35,888,624
Number of Shares, Warrants Exercised		(1,000,000)
Number of Shares, Warrants Outstanding and Exercisable Ending		413,423,972	44,806,076
Weighted Average Exercise Price Outstanding		$ 0.78	$ 1.38
Weighted Average Exercise Price Warrants Exchanged			0.40
Weighted Average Exercise Price Warrants Expired			2.73
Weighted Average Exercise Price Warrants Issued		0.01	0.73
Weighted Average Exercise Price Warrants Exercised		0.01
Weighted Average Exercise Price Outstanding and Exercisable Ending		$ 0.015	$ 0.78
Weighted Average Remaining Contractual Life Warrants Outstanding, Beginning		4 years 7 months 2 days	1 year 6 months 10 days
Weighted Average Remaining Contractual Life Warrants Outstanding, Issued		10 years 18 days	5 years 4 months 9 days
Weighted Average Remaining Contractual Life Warrants Outstanding and Exercisable		10 years 3 months 19 days	4 years 7 months 2 days

Common Stock Warrants - Schedul

Common Stock Warrants - Schedule of Assumptions for Warrants (Details)		12 Months Ended
		Dec. 31, 2020$ / sharesshares	Sep. 11, 2020shares
Number of Warrants | shares			363,146,765
Short-term Note Related Party 11/26/2019 [Member]
Number of Warrants | shares		400,000
H-CYTE Stock Price		$ 0.20
Exercise Price of Warrant		0.75
Warrant Grant Date Fair Value		$ 0.13
Life of Warrant		3 years
Short-term Note Related Party 12/30/2019 [Member]
Number of Warrants | shares		171,429
H-CYTE Stock Price		$ 0.14
Exercise Price of Warrant		0.75
Warrant Grant Date Fair Value		$ 0.08
Life of Warrant		3 years
Short-term Note Related Party 1/13/2020 [Member]
Number of Warrants | shares		268,571
H-CYTE Stock Price		$ 0.12
Exercise Price of Warrant		0.75
Warrant Grant Date Fair Value		$ 0.07
Life of Warrant		3 years
Measurement Input, Risk Free Interest Rate [Member]
Warrant Input, Percentage		0.65
Measurement Input, Risk Free Interest Rate [Member] | Short-term Note Related Party 11/26/2019 [Member]
Warrant Input, Percentage		1.58
Measurement Input, Risk Free Interest Rate [Member] | Short-term Note Related Party 12/30/2019 [Member]
Warrant Input, Percentage		1.59
Measurement Input, Risk Free Interest Rate [Member] | Short-term Note Related Party 1/13/2020 [Member]
Warrant Input, Percentage		1.60
Measurement Input, Stock Price Volatility [Member]
Warrant Input, Percentage		100.64
Measurement Input, Stock Price Volatility [Member] | Short-term Note Related Party 11/26/2019 [Member]
Warrant Input, Percentage		144.36
Measurement Input, Stock Price Volatility [Member] | Short-term Note Related Party 12/30/2019 [Member]
Warrant Input, Percentage		145.29
Measurement Input, Stock Price Volatility [Member] | Short-term Note Related Party 1/13/2020 [Member]
Warrant Input, Percentage		145.76
Private Placement 1/08/2019 [Member]
Number of Warrants | shares		5,000,000
H-CYTE Stock Price		$ 0.40
Exercise Price of Warrant		0.75
Warrant Grant Date Fair Value		$ 0.24
Life of Warrant		3 years
Private Placement 1/08/2019 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant Input, Percentage		2.57
Private Placement 1/08/2019 [Member] | Measurement Input, Stock Price Volatility [Member]
Warrant Input, Percentage		115.08
Antidilution Provision 1/08/2019 [Member]
Number of Warrants | shares	[1]	2,023,438
H-CYTE Stock Price	[1]	$ 0.40
Exercise Price of Warrant	[1]	0.40
Warrant Grant Date Fair Value	[1]	$ 0.28
Life of Warrant	[1]	3 years
Antidilution Provision 1/08/2019 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant Input, Percentage	[1]	2.57
Antidilution Provision 1/08/2019 [Member] | Measurement Input, Stock Price Volatility [Member]
Warrant Input, Percentage	[1]	115.08
Private Placement 1/18/2019 [Member]
Number of Warrants | shares		6,000,000
H-CYTE Stock Price		$ 0.40
Exercise Price of Warrant		0.75
Warrant Grant Date Fair Value		$ 0.23
Life of Warrant		3 years
Private Placement 1/18/2019 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant Input, Percentage		2.60
Private Placement 1/18/2019 [Member] | Measurement Input, Stock Price Volatility [Member]
Warrant Input, Percentage		114.07
Private Placement 1/25/2019 [Member]
Number of Warrants | shares		1,250,000
H-CYTE Stock Price		$ 0.59
Exercise Price of Warrant		0.75
Warrant Grant Date Fair Value		$ 0.38
Life of Warrant		3 years
Private Placement 1/25/2019 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant Input, Percentage		2.43
Private Placement 1/25/2019 [Member] | Measurement Input, Stock Price Volatility [Member]
Warrant Input, Percentage		113.72
Private Placement 1/31/2019 [Member]
Number of Warrants | shares		437,500
H-CYTE Stock Price		$ 0.54
Exercise Price of Warrant		0.75
Warrant Grant Date Fair Value		$ 0.34
Life of Warrant		3 years
Private Placement 1/31/2019 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant Input, Percentage		2.43
Private Placement 1/31/2019 [Member] | Measurement Input, Stock Price Volatility [Member]
Warrant Input, Percentage		113.47
Private Placement 2/7/2019 [Member]
Number of Warrants | shares		750,000
H-CYTE Stock Price		$ 0.57
Exercise Price of Warrant		0.75
Warrant Grant Date Fair Value		$ 0.36
Life of Warrant		3 years
Private Placement 2/7/2019 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant Input, Percentage		2.46
Private Placement 2/7/2019 [Member] | Measurement Input, Stock Price Volatility [Member]
Warrant Input, Percentage		113.23
Private Placement 2/22/2019 [Member]
Number of Warrants | shares		375,000
H-CYTE Stock Price		$ 0.49
Exercise Price of Warrant		0.75
Warrant Grant Date Fair Value		$ 0.30
Life of Warrant		3 years
Private Placement 2/22/2019 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant Input, Percentage		2.46
Private Placement 2/22/2019 [Member] | Measurement Input, Stock Price Volatility [Member]
Warrant Input, Percentage		113.34
Private Placement 3/1/2019 [Member]
Number of Warrants | shares		125,000
H-CYTE Stock Price		$ 0.52
Exercise Price of Warrant		0.75
Warrant Grant Date Fair Value		$ 0.33
Life of Warrant		3 years
Private Placement 3/1/2019 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant Input, Percentage		2.54
Private Placement 3/1/2019 [Member] | Measurement Input, Stock Price Volatility [Member]
Warrant Input, Percentage		113.42
Private Placement 3/8/2019 [Member]
Number of Warrants | shares		150,000
H-CYTE Stock Price		$ 0.59
Exercise Price of Warrant		0.75
Warrant Grant Date Fair Value		$ 0.38
Life of Warrant		3 years
Private Placement 3/8/2019 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant Input, Percentage		2.43
Private Placement 3/8/2019 [Member] | Measurement Input, Stock Price Volatility [Member]
Warrant Input, Percentage		113.53
Private Placement 3/11/2019 [Member]
Number of Warrants | shares		2,475,000
H-CYTE Stock Price		$ 0.61
Exercise Price of Warrant		0.75
Warrant Grant Date Fair Value		$ 0.40
Life of Warrant		3 years
Private Placement 3/11/2019 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant Input, Percentage		2.45
Private Placement 3/11/2019 [Member] | Measurement Input, Stock Price Volatility [Member]
Warrant Input, Percentage		113.62
Private Placement 3/26/2019 [Member]
Number of Warrants | shares		500,000
H-CYTE Stock Price		$ 0.51
Exercise Price of Warrant		0.75
Warrant Grant Date Fair Value		$ 0.32
Life of Warrant		3 years
Private Placement 3/26/2019 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant Input, Percentage		2.18
Private Placement 3/26/2019 [Member] | Measurement Input, Stock Price Volatility [Member]
Warrant Input, Percentage		113.12
Private Placement 3/28/2019 [Member]
Number of Warrants | shares		375,000
H-CYTE Stock Price		$ 0.51
Exercise Price of Warrant		0.75
Warrant Grant Date Fair Value		$ 0.31
Life of Warrant		3 years
Private Placement 3/28/2019 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant Input, Percentage		2.18
Private Placement 3/28/2019 [Member] | Measurement Input, Stock Price Volatility [Member]
Warrant Input, Percentage		112.79
Private Placement 3/29/2019 [Member]
Number of Warrants | shares		62,500
H-CYTE Stock Price		$ 0.51
Exercise Price of Warrant		0.75
Warrant Grant Date Fair Value		$ 0.31
Life of Warrant		3 years
Private Placement 3/29/2019 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant Input, Percentage		2.21
Private Placement 3/29/2019 [Member] | Measurement Input, Stock Price Volatility [Member]
Warrant Input, Percentage		112.79
Private Placement 4/4/2019 [Member]
Number of Warrants | shares		500,000
H-CYTE Stock Price		$ 0.48
Exercise Price of Warrant		0.75
Warrant Grant Date Fair Value		$ 0.29
Life of Warrant		3 years
Private Placement 4/4/2019 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant Input, Percentage		2.29
Private Placement 4/4/2019 [Member] | Measurement Input, Stock Price Volatility [Member]
Warrant Input, Percentage		112.77
Private Placement 7/15/2019 [Member]
Number of Warrants | shares		200,000
H-CYTE Stock Price		$ 0.53
Exercise Price of Warrant		1
Warrant Grant Date Fair Value		$ 0.31
Life of Warrant		3 years
Private Placement 7/15/2019 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant Input, Percentage		1.80
Private Placement 7/15/2019 [Member] | Measurement Input, Stock Price Volatility [Member]
Warrant Input, Percentage		115.50
Convertible Debt Extension 9/18/2019 [Member]
Number of Warrants | shares		424,000
H-CYTE Stock Price		$ 0.40
Exercise Price of Warrant		0.75
Warrant Grant Date Fair Value		$ 0.25
Life of Warrant		3 years
Convertible Debt Extension 9/18/2019 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant Input, Percentage		1.72
Convertible Debt Extension 9/18/2019 [Member] | Measurement Input, Stock Price Volatility [Member]
Warrant Input, Percentage		122.04
Private Placement of Series D Convertible Preferred Stock 11/15/2019 [Member]
Number of Warrants | shares		14,669,757
H-CYTE Stock Price		$ 0.28
Exercise Price of Warrant		0.75
Warrant Grant Date Fair Value		$ 0.19
Life of Warrant		10 years
Private Placement of Series D Convertible Preferred Stock 11/15/2019 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant Input, Percentage		1.84
Private Placement of Series D Convertible Preferred Stock 11/15/2019 [Member] | Measurement Input, Stock Price Volatility [Member]
Warrant Input, Percentage		89.75
Private Placement of Series D Convertible Preferred Stock 1/17/2020 [Member]
Number of Warrants | shares		244,996
H-CYTE Stock Price		$ 0.15
Exercise Price of Warrant		0.75
Warrant Grant Date Fair Value		$ 0.13
Life of Warrant		10 years
Private Placement of Series D Convertible Preferred Stock 1/17/2020 [Member] | Measurement Input, Stock Price Volatility [Member]
Warrant Input, Percentage		144.30
Private Placement of Series D Convertible Preferred Stock 1/17/2020 [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrant Input, Percentage		1.84
Granted for Bridge Financing 04/08/2020 [Member]
Number of Warrants | shares		296,875
H-CYTE Stock Price		$ 0.05
Exercise Price of Warrant		0.40
Warrant Grant Date Fair Value		$ 0.02
Life of Warrant		3 years
Granted for Bridge Financing 04/08/2020 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant Input, Percentage		0.34
Granted for Bridge Financing 04/08/2020 [Member] | Measurement Input, Stock Price Volatility [Member]
Warrant Input, Percentage		131.82
Short Term Note, Related Party Conversion 04/17/2020 [Member]
Number of Warrants | shares		4,368,278
H-CYTE Stock Price		$ 0.05
Exercise Price of Warrant		0.014
Warrant Grant Date Fair Value		$ 0.05
Life of Warrant		10 years
Granted for Bridge Financing 9/11/2020 [Member]
Number of Warrants | shares	[2]	364,439,176
H-CYTE Stock Price	[2]	$ 0.05
Exercise Price of Warrant	[2]	0.014
Warrant Grant Date Fair Value	[2]	$ 0.017
Life of Warrant	[2]	10 years
Granted for Bridge Financing 9/11/2020 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant Input, Percentage	[2]	0.65
Granted for Bridge Financing 9/11/2020 [Member] | Measurement Input, Stock Price Volatility [Member]
Warrant Input, Percentage	[2]	96.97
[1]	The Company had warrants that triggered the required issuance of an additional 2,023,438 warrants as a result of the Company's capital raise that gave those new investors a $0.40 per share investment price which required the old warrant holders to receive additional warrants since their price was $0.75 per share.
[2]	The Company had estimated on April 17, 2020 that the number of warrants to be granted for the bridge financing would be 354,836,286. The bridge financing closed on September 11, 2020 in which an additional 8,310,479 warrants were issued above the original estimate for a total of 363,146,765. The fair market value associated with the additional warrants issued was recorded to the change in fair value of derivative liability - warrants prior to being reclassed to equity. Upon closing of the Rights Offering on September 11, 2020, the Company issued warrants to one of the Series B Preferred shareholders of 1,292,411 due to an anti-dilution feature embedded in the Series B warrant.

Common Stock Warrants - Sched_2

Common Stock Warrants - Schedule of Assumptions for Warrants (Details) (Parenthetical) - USD ($)	Sep. 11, 2020	Apr. 17, 2020	Dec. 31, 2020	Dec. 31, 2019
Additional warrant	$ 8,310,479
Number of warrant granted		354,836,286	369,617,896	35,888,624
Number of Warrants	363,146,765
Series B Warrant [Member]
Number of warrants issued	1,292,411
Antidilution Provision 1/08/2019 [Member]
Additional warrant			$ 2,023,438
Investment price			$ 0.40
Warrants exercise price, per share			$ 0.75

Mezzanine Equity and Series D_3

Mezzanine Equity and Series D Convertible Preferred Stock (Details Narrative) - USD ($)	Jul. 28, 2020	Jan. 17, 2020	Nov. 21, 2019	Nov. 15, 2019	Feb. 28, 2019	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Sep. 11, 2020	Mar. 31, 2019	Jan. 08, 2019
Share issued price per share										$ 0.40
Redemption put liability	$ 0					$ 267,399		$ 267,399
Proceeds form shares								4,337,106
Shares issued during period, value								$ 4,419,787
Debt conversion of common stock shares					250,000
Series D Convertible Preferred Stock [Member]
Deemed dividends							$ 278,000
Cumulative dividends, percentage							8.00%
Shares issued during period, value							$ 6,401,762
FWHC HOLDINGS, LLC [Member]
Warrant term									10 years
Warrants exercise price, per share									$ 0.014
Series D Convertible Preferred Stock [Member]
Debt conversion of common stock shares	15,773,363
Securities Purchase Agreement [Member]
Proceeds from warrants						$ 245,000
Debt conversion price per share						$ 0.40		$ 0.40			$ 0.40
Debt conversion of common stock shares								1,875,000
Securities Purchase Agreement [Member] | FWHC HOLDINGS, LLC [Member]
Stock issued during period new issue shares			146,998
Proceeds from warrants			$ 6,000,000
Convertible, beneficial conversion feature								$ 623,000
Securities Purchase Agreement [Member] | Series D Shares [Member] | FWHC HOLDINGS, LLC [Member]
Preferred stock, par value, per share			$ 0.001
Securities Purchase Agreement [Member] | Series D Shares and Warrants [Member] | FWHC HOLDINGS, LLC [Member]
Share issued price per share		$ 0.001				0.28		$ 0.28
Convertible, beneficial conversion feature								$ 623,045
Debt conversion price per share						0.24		$ 0.24
Beneficial conversion feature, per share						$ 0.04		$ 0.04
Preferred stock, discount on shares			$ 3,130,146
Redemption value of preferred stock		$ 100,000	$ 6,000,000
Purchase of shares		2,450
Preferred stock redemption discount		$ 37,207
Proceeds form shares		$ 100,000
Securities Purchase Agreement [Member] | Accredited Investors [Member] | Series D Convertible Preferred Stock [Member]
Share issued price per share				$ 40.817
Securities Purchase Agreement [Member] | Accredited Investors [Member] | Maximum [Member] | Series D Convertible Preferred Stock [Member]
Stock issued during period new issue shares				238,871
Securities Purchase Agreement [Member] | Accredited Investors [Member] | Series D Convertible Preferred Stock [Member]
Warrant term				10 years
Number of warrants to purchase common stock				14,669,757
Warrants exercise price, per share				$ 0.75

Mezzanine Equity and Series D_4

Mezzanine Equity and Series D Convertible Preferred Stock - Schedule of Series D Convertible Preferred and Warrant Financing (Details) - USD ($)	Jan. 17, 2020	Nov. 21, 2019	Dec. 31, 2019
Gross proceeds		$ 6,000,000
Financing costs paid in cash		(111,983)
Proceeds from issuance of preferred stock and warrants, net of financing cost		(5,888,017)
Financing costs (APIC)			$ 2,663,797
Investor Warrants [Member]
Proceeds from issuance of preferred stock and warrants, net of financing cost		(5,888,017)
Proceeds allocation		(1,893,006)
Financing costs (APIC)		36,512
Redeemable Preferred Stock [Member]
Series D Convertible Preferred Stock		(2,869,854)
Financing costs (APIC)		1,106
Financing costs (Retained Earnings)		66,265
Beneficial Conversion Feature		(623,045)
Derivative Liability [Member]
Derivative Put Liability		(614,095)
Deferred Financing costs		8,100
Proceeds Allocation [Member]
Gross proceeds	$ 100,000	6,000,000
Financing costs paid in cash
Proceeds from issuance of preferred stock and warrants, net of financing cost	100,000	6,000,000
Proceeds Allocation [Member] | Investor Warrants [Member]
Proceeds from issuance of preferred stock and warrants, net of financing cost	(100,000)	(6,000,000)
Proceeds allocation	(31,902)	(1,893,006)
Financing costs (APIC)
Proceeds Allocation [Member] | Redeemable Preferred Stock [Member]
Series D Convertible Preferred Stock	(62,793)	(2,869,854)
Financing costs (APIC)
Financing costs (Retained Earnings)
Beneficial Conversion Feature		(623,045)
Proceeds Allocation [Member] | Derivative Liability [Member]
Derivative Put Liability	$ (5,305)	(614,095)
Deferred Financing costs
Financing Cost Allocation [Member]
Gross proceeds
Financing costs paid in cash		(111,983)
Proceeds from issuance of preferred stock and warrants, net of financing cost		(111,983)
Financing Cost Allocation [Member] | Investor Warrants [Member]
Proceeds from issuance of preferred stock and warrants, net of financing cost		111,983
Proceeds allocation
Financing costs (APIC)		36,512
Financing Cost Allocation [Member] | Redeemable Preferred Stock [Member]
Series D Convertible Preferred Stock
Financing costs (APIC)		1,106
Financing costs (Retained Earnings)		66,265
Beneficial Conversion Feature
Financing Cost Allocation [Member] | Derivative Liability [Member]
Derivative Put Liability
Deferred Financing costs		$ 8,100

Mezzanine Equity and Series D_5

Mezzanine Equity and Series D Convertible Preferred Stock - Schedule of Shares Outstanding (Details) - Series D Convertible Preferred Stock [Member] - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Beginning balance	$ 6,060,493
Issuance of Series D Convertible Preferred Stock	62,793	$ 2,869,853
Inception deemed dividend	37,207	3,130,147
Deemed dividend (8%)	277,719	60,493
Mandatory conversion of Series D Convertible Preferred Stock to Common Stock	(6,438,212)
Ending balance		$ 6,060,493

Mezzanine Equity and Series D_6

Mezzanine Equity and Series D Convertible Preferred Stock - Schedule of Shares Outstanding (Details) (Parenthetical)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Series D Convertible Preferred Stock [Member]
Deemed dividend percentage	8.00%	8.00%

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Deferred tax asset valuation allowance	$ 12,510,237	$ 10,536,250
U.S. Federal [Member]
Operating loss carryforwards	$ 39,700,000
Operating loss carryforwards, description	Company had $39.7 million of U.S. federal net operating loss carryforwards available to reduce future taxable income, of which $32.5 million will be carried forward indefinitely for U.S. federal tax purposes and $7.2 million will expire beginning in 2035 to 2037.
U.S. State [Member]
Operating loss carryforwards	$ 26,000,000
Operating loss carryforwards, description	The Company also has $26.0 million of U.S. state net operating loss carryforwards of which $25.3 million will be carried forward indefinitely and $.7 million that will expire beginning in 2035 to 2037.

Income Taxes - Schedule of Comp

Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Statutory rate - federal	21.00%	21.00%
State income tax, net of federal benefit	5.10%	3.00%
State NOL true-up	(1.10%)	(2.00%)
Goodwill impairment	0.00%	(9.00%)
Prior year true up	2.70%	0.00%
Other permanent differences	3.00%	(1.00%)
Change in valuation allowances	(30.70%)	(13.00%)
Total	0.00%	0.00%

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Federal and state net operating loss carry forwards	$ 9,512,596	$ 7,302,375
Capitalized start-up costs	2,210,392	2,483,736
Capitalized research and development costs	462,768	424,390
Patents	41,842	57,907
Share-based compensation	241,177	242,437
Other	112,376	25,405
Total gross deferred tax assets	12,581,151	10,536,250
Right-of-use asset	(70,914)
Total gross deferred tax liabilities	(70,914)
Valuation Allowance	(12,510,237)	(10,536,250)
Net deferred tax assets

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Series A Preferred Stock [Member] - shares	Mar. 24, 2021	Dec. 31, 2020
Shares converted into common stock		4,020,031
Subsequent Event [Member]
Shares converted into common stock	8,950,400